WO2011148983A1 - 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 - Google Patents
生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 Download PDFInfo
- Publication number
- WO2011148983A1 WO2011148983A1 PCT/JP2011/062006 JP2011062006W WO2011148983A1 WO 2011148983 A1 WO2011148983 A1 WO 2011148983A1 JP 2011062006 W JP2011062006 W JP 2011062006W WO 2011148983 A1 WO2011148983 A1 WO 2011148983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- cancer
- induced
- cells
- genes
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 425
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 422
- 201000011510 cancer Diseases 0.000 title claims abstract description 400
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 42
- 230000003211 malignant effect Effects 0.000 title claims description 198
- 230000006698 induction Effects 0.000 title claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 804
- 210000004027 cell Anatomy 0.000 claims abstract description 349
- 101150037203 Sox2 gene Proteins 0.000 claims abstract description 48
- 230000005856 abnormality Effects 0.000 claims abstract description 45
- 101150082761 POU5F1 gene Proteins 0.000 claims abstract description 42
- 238000000338 in vitro Methods 0.000 claims abstract description 32
- 101150012532 NANOG gene Proteins 0.000 claims abstract description 18
- 101150111214 lin-28 gene Proteins 0.000 claims abstract description 18
- 101150047500 TERT gene Proteins 0.000 claims abstract description 16
- 101100545244 Homo sapiens ZFP42 gene Proteins 0.000 claims abstract description 15
- 101150094396 ZFP42 gene Proteins 0.000 claims abstract description 15
- 230000001939 inductive effect Effects 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims description 144
- 210000001519 tissue Anatomy 0.000 claims description 140
- 210000001082 somatic cell Anatomy 0.000 claims description 115
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 79
- 210000001900 endoderm Anatomy 0.000 claims description 78
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 49
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 49
- 230000035772 mutation Effects 0.000 claims description 49
- 241000124008 Mammalia Species 0.000 claims description 48
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 44
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 34
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 33
- 206010017758 gastric cancer Diseases 0.000 claims description 33
- 201000011549 stomach cancer Diseases 0.000 claims description 33
- 101100510266 Homo sapiens KLF4 gene Proteins 0.000 claims description 30
- 101150070299 KLF4 gene Proteins 0.000 claims description 30
- 238000012216 screening Methods 0.000 claims description 30
- 208000029742 colonic neoplasm Diseases 0.000 claims description 23
- 206010009944 Colon cancer Diseases 0.000 claims description 22
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims description 19
- 230000033115 angiogenesis Effects 0.000 claims description 17
- 229940022399 cancer vaccine Drugs 0.000 claims description 16
- 230000037361 pathway Effects 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 238000009566 cancer vaccine Methods 0.000 claims description 15
- 206010027476 Metastases Diseases 0.000 claims description 14
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 14
- 230000009545 invasion Effects 0.000 claims description 14
- 230000009401 metastasis Effects 0.000 claims description 14
- 230000019491 signal transduction Effects 0.000 claims description 14
- 230000004888 barrier function Effects 0.000 claims description 13
- 210000003494 hepatocyte Anatomy 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010059866 Drug resistance Diseases 0.000 claims description 11
- 206010021143 Hypoxia Diseases 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 230000007954 hypoxia Effects 0.000 claims description 11
- 201000007270 liver cancer Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 10
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 108010038795 estrogen receptors Proteins 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 230000009456 molecular mechanism Effects 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 231100000504 carcinogenesis Toxicity 0.000 claims description 9
- 230000036267 drug metabolism Effects 0.000 claims description 9
- 208000005623 Carcinogenesis Diseases 0.000 claims description 8
- 102000048850 Neoplasm Genes Human genes 0.000 claims description 8
- 108700019961 Neoplasm Genes Proteins 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 8
- 239000003560 cancer drug Substances 0.000 claims description 8
- 230000036952 cancer formation Effects 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 230000001988 toxicity Effects 0.000 claims description 8
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 238000010171 animal model Methods 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 101150075625 Gsc gene Proteins 0.000 claims description 4
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 claims description 4
- 101100310647 Homo sapiens SOX17 gene Proteins 0.000 claims description 4
- 101150007417 SOX17 gene Proteins 0.000 claims description 4
- 101150003286 gata4 gene Proteins 0.000 claims description 4
- 101150002130 Rb1 gene Proteins 0.000 claims description 3
- 239000012830 cancer therapeutic Substances 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 108700001666 APC Genes Proteins 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 241000027355 Ferocactus setispinus Species 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 238000011160 research Methods 0.000 abstract description 19
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 description 280
- 238000012546 transfer Methods 0.000 description 134
- 239000002609 medium Substances 0.000 description 114
- 239000000523 sample Substances 0.000 description 81
- 239000013598 vector Substances 0.000 description 57
- 239000000243 solution Substances 0.000 description 41
- 238000000018 DNA microarray Methods 0.000 description 37
- 239000006228 supernatant Substances 0.000 description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 239000008103 glucose Substances 0.000 description 28
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 25
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 25
- 230000001177 retroviral effect Effects 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 22
- 238000004321 preservation Methods 0.000 description 21
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 20
- 239000006285 cell suspension Substances 0.000 description 20
- 239000003429 antifungal agent Substances 0.000 description 19
- 239000013592 cell lysate Substances 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 238000003860 storage Methods 0.000 description 19
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 18
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 18
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 229960004857 mitomycin Drugs 0.000 description 17
- 229930192392 Mitomycin Natural products 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 16
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108010010803 Gelatin Proteins 0.000 description 14
- 229940121375 antifungal agent Drugs 0.000 description 14
- 210000004443 dendritic cell Anatomy 0.000 description 14
- 229920000159 gelatin Polymers 0.000 description 14
- 239000008273 gelatin Substances 0.000 description 14
- 235000019322 gelatine Nutrition 0.000 description 14
- 235000011852 gelatine desserts Nutrition 0.000 description 14
- 108700028369 Alleles Proteins 0.000 description 13
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 13
- 238000007876 drug discovery Methods 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 201000000582 Retinoblastoma Diseases 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000002354 daily effect Effects 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000004602 germ cell Anatomy 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 230000000711 cancerogenic effect Effects 0.000 description 10
- 231100000315 carcinogenic Toxicity 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 102100038595 Estrogen receptor Human genes 0.000 description 8
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 8
- 206010064571 Gene mutation Diseases 0.000 description 8
- 244000060234 Gmelina philippensis Species 0.000 description 8
- -1 NANOG Proteins 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 210000001778 pluripotent stem cell Anatomy 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 101150025224 OCT3 gene Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002543 antimycotic Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 101150033839 4 gene Proteins 0.000 description 6
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 6
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 6
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 101150000629 TGFB1 gene Proteins 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000011067 equilibration Methods 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001973 epigenetic effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008672 reprogramming Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- 101150090724 3 gene Proteins 0.000 description 4
- MQGPSCMMNJKMHQ-UHFFFAOYSA-N 7-hydroxyflavone Chemical compound C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 MQGPSCMMNJKMHQ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000038624 GSKs Human genes 0.000 description 4
- 108091007911 GSKs Proteins 0.000 description 4
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 4
- 101100364841 Homo sapiens SALL4 gene Proteins 0.000 description 4
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 4
- 101150046085 INHBA gene Proteins 0.000 description 4
- 101150110522 INHBB gene Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 101150072008 NR5A2 gene Proteins 0.000 description 4
- 102100036467 Protein delta homolog 1 Human genes 0.000 description 4
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 4
- 101150041225 SALL4 gene Proteins 0.000 description 4
- 108700038175 YAP-Signaling Proteins Proteins 0.000 description 4
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108700025694 p53 Genes Proteins 0.000 description 4
- 239000003761 preservation solution Substances 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 101150113634 CDKN1A gene Proteins 0.000 description 3
- 101150008975 Col3a1 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101150009635 IGFBP3 gene Proteins 0.000 description 3
- 101710119301 Protein delta homolog 1 Proteins 0.000 description 3
- 102100032491 Serine protease 1 Human genes 0.000 description 3
- 101710151387 Serine protease 1 Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 108700025695 Suppressor Genes Proteins 0.000 description 3
- 101150111019 Tbx3 gene Proteins 0.000 description 3
- 101710119665 Trypsin-1 Proteins 0.000 description 3
- 101150010487 are gene Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000000053 blastoma Diseases 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000008184 embryoma Diseases 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- VEBWTGYUIBTVNR-MLGOLLRUSA-N (6ar,9r)-n-ethyl-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)NCC)C2)=C3C2=CNC3=C1 VEBWTGYUIBTVNR-MLGOLLRUSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 101150018057 BMP7 gene Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 101150025841 CCND1 gene Proteins 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102100028914 Catenin beta-1 Human genes 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 101150099612 Esrrb gene Proteins 0.000 description 2
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108060006662 GSK3 Proteins 0.000 description 2
- 101150072276 Gabrb3 gene Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 101150058670 Gstm3 gene Proteins 0.000 description 2
- 101150096895 HSPB1 gene Proteins 0.000 description 2
- 101150077068 Hdac5 gene Proteins 0.000 description 2
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 2
- 101100332079 Homo sapiens DNMT3B gene Proteins 0.000 description 2
- 101001053992 Homo sapiens Deleted in lung and esophageal cancer protein 1 Proteins 0.000 description 2
- 101000966403 Homo sapiens Dynein light chain 1, cytoplasmic Proteins 0.000 description 2
- 101000911317 Homo sapiens Fatty acid-binding protein, liver Proteins 0.000 description 2
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 2
- 101100175312 Homo sapiens GDF3 gene Proteins 0.000 description 2
- 101000581787 Homo sapiens GTP-binding protein REM 2 Proteins 0.000 description 2
- 101001032602 Homo sapiens Homeobox protein goosecoid Proteins 0.000 description 2
- 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 description 2
- 101100409179 Homo sapiens PRDM14 gene Proteins 0.000 description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 description 2
- 101100364835 Homo sapiens SALL1 gene Proteins 0.000 description 2
- 101100369075 Homo sapiens TDGF1 gene Proteins 0.000 description 2
- 101100484233 Homo sapiens UTF1 gene Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 101150002416 Igf2 gene Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 101150005607 Mdk gene Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 101150071658 TDGF1 gene Proteins 0.000 description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 101150079992 Timp3 gene Proteins 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- 102100034593 Tripartite motif-containing protein 26 Human genes 0.000 description 2
- 101150049188 UTF1 gene Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 101150024147 bax gene Proteins 0.000 description 2
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 2
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 101150103009 gene 17 gene Proteins 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 101150031865 ACVR2B gene Proteins 0.000 description 1
- 101150111620 AQP1 gene Proteins 0.000 description 1
- 101150072037 ATP6V0C gene Proteins 0.000 description 1
- 101150075644 ATP7B gene Proteins 0.000 description 1
- 101150069931 Abcg2 gene Proteins 0.000 description 1
- 101150020966 Acta2 gene Proteins 0.000 description 1
- 101150070360 Agt gene Proteins 0.000 description 1
- 101150095204 Aldh1a1 gene Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 1
- 101150065502 BLVRB gene Proteins 0.000 description 1
- 101150000484 BMP1 gene Proteins 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101150095033 CADM1 gene Proteins 0.000 description 1
- 101150052909 CCL2 gene Proteins 0.000 description 1
- 101150082143 CD24 gene Proteins 0.000 description 1
- 101150017002 CD44 gene Proteins 0.000 description 1
- 101150008656 COL1A1 gene Proteins 0.000 description 1
- 101150072801 COL1A2 gene Proteins 0.000 description 1
- 101150004046 COL4A2 gene Proteins 0.000 description 1
- 101150106671 COMT gene Proteins 0.000 description 1
- 101150037241 CTNNB1 gene Proteins 0.000 description 1
- 101150035856 CTSB gene Proteins 0.000 description 1
- 101150011193 CYP26A1 gene Proteins 0.000 description 1
- 102100025805 Cadherin-1 Human genes 0.000 description 1
- 101100126625 Caenorhabditis elegans itr-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101150079049 Ccnd2 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000031639 Chromosome Deletion Diseases 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 101150051061 DKK3 gene Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 101150001833 EDNRB gene Proteins 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101150025764 FGFR3 gene Proteins 0.000 description 1
- 101150061740 FRZB gene Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 101150048336 Flt1 gene Proteins 0.000 description 1
- 101150095249 Fst gene Proteins 0.000 description 1
- 101150052409 GRB7 gene Proteins 0.000 description 1
- 101150045574 GSN gene Proteins 0.000 description 1
- 101150033270 Gadd45a gene Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 101150007884 Gata6 gene Proteins 0.000 description 1
- 101150085449 Gdf15 gene Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101150050733 Gnas gene Proteins 0.000 description 1
- 101150092640 HES1 gene Proteins 0.000 description 1
- 101150044653 HMOX1 gene Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101150063906 Hdac10 gene Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102100038146 Homeobox protein goosecoid Human genes 0.000 description 1
- 101001125540 Homo sapiens 26S proteasome regulatory subunit 6A Proteins 0.000 description 1
- 101100004580 Homo sapiens BMP1 gene Proteins 0.000 description 1
- 101100273821 Homo sapiens CDKN1C gene Proteins 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101000881868 Homo sapiens Developmental pluripotency-associated protein 4 Proteins 0.000 description 1
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 description 1
- 101000915396 Homo sapiens Disabled homolog 2-interacting protein Proteins 0.000 description 1
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101001060744 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 101000657536 Homo sapiens Putative tubulin-like protein alpha-4B Proteins 0.000 description 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 1
- 101100523593 Homo sapiens RASSF1 gene Proteins 0.000 description 1
- 101100096059 Homo sapiens SMYD3 gene Proteins 0.000 description 1
- 101000864743 Homo sapiens Secreted frizzled-related protein 1 Proteins 0.000 description 1
- 101000845183 Homo sapiens Tetratricopeptide repeat protein 5 Proteins 0.000 description 1
- 101000976645 Homo sapiens Zinc finger protein ZIC 3 Proteins 0.000 description 1
- 101150047228 Id3 gene Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- 101150078927 KRT18 gene Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 101150023976 Krt19 gene Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 101150056222 MVP gene Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 101150042248 Mgmt gene Proteins 0.000 description 1
- 101150106019 Mmp2 gene Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 238000011789 NOD SCID mouse Methods 0.000 description 1
- 101150091206 Nfkbia gene Proteins 0.000 description 1
- 101150015020 Nr2f2 gene Proteins 0.000 description 1
- 101150085710 OCT4 gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
- 101150031628 PITX2 gene Proteins 0.000 description 1
- 101150108126 PLAU gene Proteins 0.000 description 1
- 101150048468 PODXL gene Proteins 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100034805 Putative tubulin-like protein alpha-4B Human genes 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150098078 RASSF1 gene Proteins 0.000 description 1
- 101150041202 RASSF2 gene Proteins 0.000 description 1
- 101150061360 RBP1 gene Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 101150067744 Rgs2 gene Proteins 0.000 description 1
- 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 description 1
- 101150056859 S100a4 gene Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101150085279 SLC16A3 gene Proteins 0.000 description 1
- 101150093801 SLC9A3R1 gene Proteins 0.000 description 1
- 101150093844 SMYD3 gene Proteins 0.000 description 1
- 101150036757 SPARC gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000009125 Sigmoid Neoplasms Diseases 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150025711 TF gene Proteins 0.000 description 1
- 101150053753 TFF1 gene Proteins 0.000 description 1
- 101150077804 TIMP1 gene Proteins 0.000 description 1
- 101150091380 TTR gene Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100031280 Tetratricopeptide repeat protein 5 Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101150021063 Timp2 gene Proteins 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101150045341 Ubb gene Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 101150018417 VIM gene Proteins 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 101150016852 Zic1 gene Proteins 0.000 description 1
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 101150055123 afp gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 101150083915 cdh1 gene Proteins 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 101150102995 dlk-1 gene Proteins 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 101150057053 fzd2 gene Proteins 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 238000000574 gas--solid chromatography Methods 0.000 description 1
- 101150101299 gene 4 gene Proteins 0.000 description 1
- 101150000808 hand1 gene Proteins 0.000 description 1
- MAHXCOMHJBHBGO-RTKIROINSA-N hematoxin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H](OC)C11C=CC(=O)C(O)=C1OC2 MAHXCOMHJBHBGO-RTKIROINSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 101150070593 lox gene Proteins 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 101150050780 nodal gene Proteins 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940118537 p53 inhibitor Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 101150097768 prmt5 gene Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010034596 procollagen Type III-N-terminal peptide Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 201000003825 sigmoid colon cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to induced precancerous stem cells or induced malignant stem cells, which have abnormalities such as mutations in endogenous tumor suppressor genes, increased expression of endogenous cancer-related genes, POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene Induced precancerous stem cells or induced malignant stem cells capable of self-replication in vitro expressing self-replication-related genes such as LIN28 gene and TERT gene (hereinafter collectively referred to as “induced cancer stem cells” in the present invention). ), These production methods, and applications of these cells.
- embryonic stem cells also referred to as “ES cells”.
- embryonic stem cells also referred to as “embryonic stem cells”
- somatic cell clones such as the creation of somatic clone embryonic stem cells and somatically cloned animals
- epigenetics DNA methylation and histone modification
- reprogramming it has become like this.
- OCT3 / 4 gene sometimes referred to as “OCT3 gene”, “OCT4 gene”, or “POU5F1 gene”
- SOX2 gene SOX2 gene
- KLF4 gene c-MYC gene
- Non-patent Document 2 Induced pluripotent stem cells (induced Pluripotent) from human somatic cells by introduction of OCT3 / 4 gene, SOX2 gene and KLF4 gene
- bFGF or FGF2 basic fibroblast growth factor
- Human induced pluripotent stem cells maintained (1) pluripotency into three germ layers, which can be any cell that forms the body, and (2) human embryonic stem cell self-replicating culture conditions. It is known to have two characteristics of self-replicating ability that can be subcultured indefinitely in a culture dish. And this human induced pluripotent stem cell is very similar to human embryonic stem cell in morphology, gene expression, cell surface antigen, long-term self-renewal ability, teratoma (differentiation into three germ layers in vivo) Furthermore, it has been reported that the genotype of HLA is exactly the same as the somatic cell that is the derived cell (Non-patent Document 4).
- Non-patent Document 6 mouse melanoma cells, which are cancer cells, have been reprogrammed into induced pluripotent stem cells
- OCT3 / 4 gene OCT3 / 4 gene
- SOX2 gene SOX2 gene
- KLF4 gene c-MYC gene
- induced pluripotent stem cells that have lost BCR-ABL tyrosine kinase dependency have been generated from chronic myeloid leukemia cells (CML) that have BCR-ABL tyrosine kinase activity, which is the cause of carcinogenesis.
- CML chronic myeloid leukemia cells
- cancer cell lines established in conventional conventional media cause artificial chromosome abnormalities (translocations, deletions, etc.), genetic abnormalities (gene mutations), and abnormal gene expression after culture. Since epigenetic abnormalities occur prominently, there is a problem that it is difficult to retain precancerous cells that originally caused carcinogenesis in vivo and abnormalities that have occurred in cancer cells. None of these cell lines were established by culture that allowed self-replication in vitro.
- Non-patent Document 9 Monoclonal cancer stem cells are self-replicated in vitro, and long-term Not only has there been no report that the cells have been successfully cultured, but there are still reports of techniques for self-replication and amplification culture until the number of cells required for in-vitro drug discovery and cancer research is reached. Not.
- an object of the present invention is to provide an in vitro induced self-replicating induced cancer stem cell having a specific gene mutation or gene expression related to carcinogenesis and a method for producing the induced cancer stem cell.
- Another object of the present invention is to screen for cancer drug targets, screening for cancer therapeutics, screening for cancer diagnostics, etc., using the induced cancer stem cells capable of self-replication in vitro of the present invention.
- the object is to provide a method or a method for preparing a cancer vaccine using the derived cancer stem cells.
- a further object of the present invention is to provide a method for producing a cancer model animal, in which induced cancer stem cells capable of self-replication in vitro of the present invention are transplanted into a laboratory animal.
- the following requirements (1) and (2) (1) Express 6 genes (self-replication related genes) of POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene; and (2) (a) Mutation of endogenous tumor suppressor gene Or (b) having any abnormality of increased expression of endogenous cancer-related genes; An inducible cancer stem cell capable of proliferating in vitro is provided.
- the expression level of the (1) self-replication-related gene expressed in the induced cancer stem cell is 1/8 compared to the expression level of the gene expressed in the embryonic stem cell. Is preferably within 8 times.
- the induced cancer stem cell of the present invention includes (b) a group consisting of a gene group related to stress and toxicity, an epigenetics chromatin-modifying enzyme gene group, and a stem cell transcription factor gene group in addition to the increased expression of the endogenous cancer-related gene.
- a cell in which increased expression of a gene has occurred in at least one endogenous gene selected from the group of genes included in the hepatocyte-specific gene group may be used.
- genes characteristic of mesendoderm stem cells and endoderm stem cells may be expressed.
- a method of producing induced cancer stem cells capable of self-replication in vitro from non-embryonic source somatic cells selected from the group consisting of somatic cells with any abnormality in the expression of cancer-related genes comprises the step of inducing the raw somatic cell to a state in which the gene products of POU5F1 gene, KLF4 gene, and SOX2 gene are present in the raw somatic cell.
- a method for producing induced cancer stem cells is provided. When a cell is "non-embryonic" it is meant that it is not an embryonic stem cell, embryo, germ cell or primordial germ cell.
- the abundance ratio of the POU5F1 gene, the KLF4 gene, and the SOX2 gene in the raw material cells can satisfy the relationship of POU5F1 gene> SOX2 gene.
- the POU5F1 gene, the KLF4 gene, and the SOX2 gene or their gene products it is preferable to use the POU5F1, KLF4 and SOX2 genes or these gene products, and the usage ratio of these POU5F1, KLF4 and SOX2 genes or these gene products is POU5F1 gene> SOX2 Satisfies genetic relationships.
- a step of sorting and proliferating one cell per well may be included.
- a selection step for identifying and selecting a malignant property or specific marker of induced cancer stem cells capable of self-replication in vitro may be included.
- This selection step was performed by inducing treatment of (a) somatic cells collected from a mammal having a mutation of a tumor suppressor gene and non-embryonic source somatic cells collected from a mammal that has developed carcinogenesis.
- the screening step may be to compare the induced endoderm stem cells, induced pluripotent stem cells, or embryonic stem cells, and identify and select malignant properties or specific markers.
- angiogenesis-related genes In particular, angiogenesis-related genes, cancer-related pathway genes, stromal barrier-related genes, epithelial-mesenchymal transition-related genes, gastric cancer-related genes, autonomous growth-related genes, TGF ⁇ / BMP signal-related genes, Tissue invasion / metastasis related gene group, Wnt signal related gene group, signal transduction related gene group, Notch signal related gene group, breast cancer and estrogen receptor signal related gene group, colon cancer related gene group, hypoxia signal related gene group , GPCR signal related gene group, drug resistance related gene group, Hedgehog signal related gene group, PI3K-AKT signal related gene group, drug metabolism gene group, cancer molecular mechanism gene group, SMAD signal network related gene group, pancreatic cancer related Included in the group consisting of gene group, prostate cancer related gene group, liver cancer related gene group, lung cancer related gene group That is selected from the group of genes, by increased expression of (b) cancer-associated gene according to at least one gene, or may be a selection step of selecting and
- a screening method selected from among a screening method for cancer drug targets, a screening method for cancer therapeutic agents, and a screening method for cancer diagnostic agents, There is provided a screening method characterized by using the induced cancer stem cells.
- a method for producing a cancer vaccine characterized by using the induced cancer stem cells of the present invention.
- the induced cancer stem cells of the present invention Provided is a method for producing a cancer model animal characterized by being transplanted to a laboratory animal.
- a mutation of an endogenous tumor suppressor gene or (b) an abnormality such as an increase in the expression of an endogenous cancer-related gene, a POU5F1 gene, a NANOG gene, a SOX2 gene, a ZFP42 gene,
- An induced cancer stem cell in which a self-replication-related gene such as LIN28 gene or TERT gene is expressed, a production method thereof, and application of these cells can be carried out.
- the induced cancer stem cell of the present invention not only maintains abnormalities such as (a) mutation of a tumor suppressor gene, or (b) increased expression of a cancer-related gene, which is contained in a somatic cell, but also has characteristics of the stem cell. It also has the characteristic that it is theoretically infinitely self-replicatable. Therefore, since the induced cancer stem cells of the present invention can be subcultured for a long period of time and can be easily induced into cancer cells having the properties of tissue cells, the target screening method for cancer drug discovery, It is very useful for research on cancer treatment and research on cancer-related drug discovery, such as screening methods and screening methods for cancer diagnostic agents, cancer vaccine production methods, cancer model animal production, etc. .
- FIG. 1 is a graph plotting angiogenesis-related genes whose expression of human induced malignant stem cells GC1-5 of the present invention is more than twice as high as that of human embryonic stem cells hES_BG03 (GSM194391).
- the middle line shows the same level of gene expression compared to human embryonic stem cells, the upper line being doubled and the lower line being 1/2 times.
- FIG. 2 is a plot of epithelial-mesenchymal transition-related genes whose expression of human-induced malignant stem cells GC1-5 of the present invention is up to 2-fold higher than that of human embryonic stem cells hES_BG03 (GSM194391).
- FIG. 3 is a plot of TGF ⁇ / BMP signal-related genes in which the expression of human induced malignant stem cells GC1-5 of the present invention is up to 2-fold higher than that of human induced pluripotent stem cells hiPS-201B7.
- the middle line shows the same level of gene expression as human induced pluripotent stem cells, the upper line is doubled, and the lower line is 1/2 times.
- FIG. 4 is a plot of tissue invasion / metastasis-related genes in which the expression of human induced malignant stem cells NGC1-1 of the present invention is more than twice as high as that of human induced pluripotent stem cells hiPS-201B7.
- the middle line shows the same level of gene expression as human induced pluripotent stem cells, the upper line is doubled, and the lower line is 1/2 times.
- FIG. 5 is a plot of Wnt signal-related genes in which the expression of human induced malignant stem cells NGC1-1 of the present invention is more than twice as high as that of human embryonic stem cells hES_H9 (GSM194390).
- FIG. 6 is a plot of self-replication-related genes in which human-induced malignant stem cells GC1-5 of the present invention were expressed at approximately the same level (1/2 to 2-fold) as human embryonic stem cells hES_H9 (GSM194390). is there.
- the middle line shows the same level of gene expression as human embryonic stem cells, the upper line is twice, and the lower line is 1/2 times.
- FIG. 7 is a plot of self-replication-related genes that were expressed in human induced malignant stem cells NGC1-1 of the present invention at approximately the same level (1/2 to 2 times) as human embryonic stem cells hES_BG03.
- the middle line shows the same level of gene expression as human embryonic stem cells, the upper line is twice, and the lower line is 1/2 times.
- FIG. 8 is a plot of self-replication-related genes that were expressed in human induced malignant stem cells CC1-10 of the present invention at approximately the same level (1/4 to 4 times) as human embryonic stem cells hES_BG03.
- the middle line shows the same level of gene expression as human embryonic stem cells, the upper line is 4 times, and the lower line is 1/4 times.
- FIG. 9 is a plot of angiogenesis-related genes whose expression of human induced malignant stem cells RBT203 (1-1) is more than twice as high as that of human embryonic stem cells hES_ES01 (GSM194392).
- the middle line shows the same level of gene expression compared to human embryonic stem cells, the upper line being doubled and the lower line being 1/2 times.
- FIG. 10 is a plot of signal transduction-related genes in which expression of human induced malignant stem cells RBT203 (1-1) is up to 2 times higher than that of human induced pluripotent stem cells hiPS-201B7.
- the middle line shows the same level of gene expression compared to human-induced pluripotent stem cells, the upper line is doubled and the lower line is half-fold.
- Fig. 11 is a plot of self-replication-related genes in which human-induced malignant stem cell RBT203 (1-1) is expressed at approximately the same level (1/2 to 2-fold) compared to human embryonic stem cell hES_ES01 (GSM194392) It is.
- the middle line shows the same level of gene expression as human embryonic stem cells, the upper line is twice, and the lower line is 1/2 times.
- somatic cells can be reprogrammed into induced pluripotent stem cells, and the concept that cancer cells can be returned to normal cells by reprogramming them. Is firmly established.
- cancer tissues or cancer cell groups Some normal and non-cancer cells with the same or similar genetics and epigenetics as normal cells are mixed, so cancer cells are not reprogrammed into normal cells, but fresh.
- Non-cancer cells and normal cells mixed in cancer tissue and primary cultured cancer cell population are induced by normal induced pluripotent stem cells, while in fresh cancer tissue and primary cultured cancer cell population Hypothesis that existing cancer cells with cancer suppressor gene mutations, abnormal gene expression, etc. induce cancer stem cells with cancer suppressor gene mutations, abnormal gene expression, etc. Stood up.
- inducible pluripotent stem cell production technology such as introduction of POU5F1, SOX2, KLF4, and c-MYC genes, or introduction of POU5F1, SOX2, and KLF4 genes.
- Induced cancer stem cells capable of self-replication can be prepared by the self-replication of the obtained induced cancer stem cells in vitro and genetically or epigenetically malignant as cancer. Induced cancer stem cells that maintain their properties and are capable of self-replication in vitro can be proliferated indefinitely under culture conditions.
- the present inventors have collected, as a raw material, somatic cells collected from a mammal having a mutation of an endogenous tumor suppressor gene, as well as collected from a mammal that has developed carcinogenesis.
- the present inventors have found that induced cancer stem cells capable of self-replication in vitro can be obtained by using non-embryonic cells and allowing the POU5F1, KLF4, and SOX2 gene gene products to be present in the source somatic cells. .
- the intracellular ratio of the gene products of the POU5F1, KLF4, and SOX2 genes is considered to be one of the important factors that determine differentiation when the somatic cells are placed in such a state.
- induced mesendoderm stem cells and induced endoderm stem cells can be prepared by changing the intracellular abundance ratio of POU5F1 gene, KLF4 gene, SOX2 gene and the like. That is, the present inventors changed the intracellular abundance ratio of the translation products of the SOX2 gene, POU5F1 gene and KLF4 gene to thereby induce induced mesendoderm precancerous stem cells or induced mesendoderm malignant stem cells, induced endoderm
- the induced cancer stem cells of the present invention can be produced, such as systemic precancer stem cells or induced endoderm malignant stem cells, induced precancerous pluripotent stem cells or induced malignant pluripotent stem cells.
- the induced cancer stem cells of the present invention are induced to differentiate by a method such as culture in a medium other than bFGF-removed medium, medium for embryonic stem cells, transplantation to experimental animals, etc. By releasing self-replication, it can be easily induced in cancer cells.
- the present inventors maintain gene mutation or increased gene expression, that is, malignant properties as cancer in the living body, that is, abnormalities of the somatic cells, and theoretically infinitely.
- the “cancer suppressor gene” is a gene that encodes a protein having a function of suppressing the occurrence of cancer, and is a gene that is mutated in the induced cancer stem cell of the present invention.
- the “cancer-related gene” in the present invention is a gene that causes canceration of a cell due to abnormal gene expression, and a gene that is related to canceration of the cell. In the induced cancer stem cell of the present invention, It means a gene causing an increase in gene expression.
- Induced cancer stem cell In the first embodiment of the present invention, the following requirements (1) and (2): (1) express 6 genes (self-replication related gene) of POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene; and (2) (a) mutation of endogenous tumor suppressor gene, Or (b) having any abnormality of increased expression of endogenous cancer-related genes;
- An induced cancer stem cell characterized by comprising: It was revealed that cells having such characteristics are induced cancer stem cells capable of self-replication in vitro.
- endogenous in (1) self-replication-related genes, (2) (a) endogenous cancer-suppressing genes, (b) endogenous cancer-related genes, etc. means that these genes are gene transfer This means that it is not a foreign gene introduced into a cell by the above method but a gene originally present in the cell.
- the term “stem cell” generally refers to the ability to differentiate into a specific cell (differentiation ability) and the ability to maintain the same properties (differentiation ability) as the original cell even after cell division (self-replication).
- the self-replicating ability means that the same cells can be produced by dividing.
- the cells having the properties (1) and (2) of the present invention they are grown or passaged for at least 3 days. It means that culture is possible.
- the induced cancer stem cell of the present invention is a concept including “pre-induction cancer stem cell” and “induced malignant stem cell”.
- the “induced precancerous stem cell” is a somatic cell having a genetic abnormality that causes a familial tumor in one side allele, a precancerous cell in a preliminary stage for canceration, and the POU5F1 gene It means a cell induced to have at least self-replication ability by expressing 6 genes (self-replication-related genes) of NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene.
- induced malignant stem cells are cells having increased expression of endogenous cancer-related genes, and are 6 genes of POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene Cells that are induced to express at least self-replication ability by expressing (self-replication-related genes) or somatic cells that have at least one-sided allele that causes a familial tumor, and are familial tumors Produced from cells derived from cancer tissue of patients and expresses 6 genes (self-replication related genes) of POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene. Means the induced cell.
- the induced cancer stem cells of the present invention include not only induced cancer stem cells exhibiting pluripotency but also mesendoderm-type and endoderm-type induced cancer stem cells.
- mesendoderm stem cell means a stem cell capable of differentiating into a cell belonging to a mesodermal or endoderm tissue and expressing a mesoendoderm gene. And cells that differentiate into blood vessels, blood cells, muscles, bones, cartilage, myocardium, skeletal muscles, stomach, lungs, pancreas, liver, small intestine, large intestine, and the like.
- endodermal stem cell refers to a stem cell that is present in the differentiation hierarchy below the mesendoderm stem cell and has the ability to differentiate into a cell belonging to an endoderm tissue. Means a cell expressing an endoderm gene. These stem cells are cells that differentiate into stomach, lung, pancreas, liver, small intestine, large intestine and the like.
- the gene (1) (self-replication-related gene) in the present invention is a gene known as a marker gene for embryonic stem cells. These genes are cells that have the property that the induced cancer stem cells of the present invention theoretically self-replicate indefinitely and can be subcultured for a long time as induced cancer stem cells that are capable of self-replication in vitro. It is a gene (self-replication related gene) that identifies a certain thing. Specific examples of these genes include the genes in Table 1 below.
- the present invention (1) six genes (self-replication-related genes) of POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene selected from the gene group of Table 1 are expressed. However, more genes may be expressed.
- the six genes listed in the present invention are genes that are known to be particularly typical genes that are specific and highly expressed in embryonic stem cells, and these genes in embryonic stem cells The function has been well examined so far.
- the (1) self-replication-related genes are expressed, and the expression level of these genes is not particularly limited, but is expressed in the induced cancer stem cells of the present invention.
- the expression level of the self-replication-related gene is compared with the expression level of the gene expressed in embryonic stem cells (for example, any of hES_H9 (GSM194390), hES_BG03 (GSM194391), hES_ES01 (GSM194392))
- embryonic stem cells for example, any of hES_H9 (GSM194390), hES_BG03 (GSM194391), hES_ES01 (GSM194392)
- hES_H9 GSM194390
- hES_BG03 GSM194391
- hES_ES01 GSM194392
- it is almost equivalent, ie, 1/8 to 8 times, especially 1/4 to 4 times or less. From the viewpoint of culture, it is most preferably within 1/2 to 2 times.
- the expression levels of POU5F1, NANOG, and SOX2 genes expressed in the induced cancer stem cells of the present invention are compared with the expression levels of genes expressed in embryonic stem cells.
- it is preferably 1/8 to 8 times, particularly preferably 1/4 to 4 times, and most preferably 1/2 to 2 times.
- the gene is expressed in a range of ⁇ 2 times, 10 or more genes 1/4 to 4 times, and 20 or more genes 1/8 to 8 times.
- NANOG gene POU5F1 gene, SOX2 gene, TDGF1 gene, DNMT3B gene, ZFP42 gene, TERT gene, GDF3 gene, SALL4 gene, GABRB3 gene, LIN28 gene are expressed in embryonic stem cells.
- ACVR2B gene CD24 gene, CDH1 gene, CYP26A1 gene, DNMT3B gene, DPPA4 gene, EDNRB gene, FLT1 gene, GABRB3 gene , GATA6 gene, GDF3 gene, GRB7 gene, LIN28 gene, NANOG gene, NODAL gene, PODXL gene, POU5F1 gene, SALL4 gene, SOX2 gene, TDGF1 gene, TERT gene, ZFP42 gene, ZIC3 gene Is most preferred.
- the induced cancer stem cells of the present invention have either (2) (a) a mutation of an endogenous tumor suppressor gene or (b) an increase in the expression of an endogenous cancer-related gene. These abnormalities possessed by the induced cancer stem cells of the present invention are directly inherited from the abnormalities originally possessed by the somatic cells from which the induced cancer stem cells are derived.
- (2) (a) when referring to a mutation of an endogenous tumor suppressor gene any type of mutation may be used.
- a germline mutation related to a single allele of an endogenous tumor suppressor gene Can be mentioned.
- the expression of an endogenous cancer-related gene is increased, the expression of the gene is increased more than twice as compared with the expression in embryonic stem cells.
- the gene expression may be any level as long as it is 2 times or more, for example, 3 times or more, 4 times or more, 5 times or more, 6 times or more, 7 times or more, 8 times or more, etc. Larger is preferable.
- Cancer-related gene is not particularly limited as long as it is a known gene, but Genes can be exemplified.
- examples of (a) tumor suppressor genes in the present invention include, for example, APC gene (GenBank accession number: NM - 000038.3) and RB1 gene (RB1, GenBank accession number: NM - 000321.2). it can.
- the induced cancer stem cell of the present invention in which a mutation is found in a causative gene of a familial tumor as a mutation of an endogenous tumor suppressor gene has a gene mutation / gene expression abnormality associated with familial tumor It is extremely useful for cancer research such as elucidation of carcinogenic mechanisms of familial tumors and discovery of molecular targets.
- the (b) cancer-related genes in the present invention include angiogenesis-related genes, cancer-related pathway genes, stromal barrier (extracellular matrix and adhesion molecule) -related genes, epithelial-mesenchymal transition-related Gene group, gastric cancer related gene group, autonomous proliferation related gene group, TGF ⁇ / BMP signal related gene group, tissue invasion / metastasis related gene group, Wnt signal related gene group, signal transduction related gene group, Notch signal related gene group, breast cancer And estrogen receptor signal related gene group, colon cancer related gene group, hypoxia signal related gene group, GPCR signal related gene group, drug resistance related gene group, Hedgehog signal related gene group, PI3K-AKT signal related gene group, drug Metabolic genes, cancer molecular mechanism genes, SMAD signal network related genes, pancreatic cancer related genes Examples include genes included in the group, prostate cancer-related gene group, liver cancer-related gene group, lung cancer-related gene group, and the like. In the induced cancer stem cells of the present invention, it is preferable
- genes are a group of genes in which increased expression of genes is observed in cancer cells, and analysis is performed on induced cancer stem cells that have abnormalities such as (b) increased expression of endogenous cancer-related genes. Therefore, elucidation of the carcinogenic mechanism is expected, and it is very useful for cancer research and cancer drug discovery research.
- cancer-related gene (b) described above examples include the genes described in Tables 2 to 26 below.
- GenBank accession number for each gene symbol is also exemplified, but the present invention is not limited by such description.
- angiogenesis-related genes examples include the genes shown in Table 2 below.
- cancer-related pathway gene groups include the genes shown in Table 3 below.
- interstitial barrier-related genes examples include the genes shown in Table 4 below.
- epithelial-mesenchymal transition related gene group examples include the genes shown in Table 5 below.
- gastric cancer-related genes examples include the genes shown in Table 6 below.
- Examples of the autonomous proliferation-related gene group include the genes shown in Table 7 below.
- TGF ⁇ / BMP signal-related genes examples include the genes shown in Table 8 below.
- tissue invasion / metastasis-related genes include the genes shown in Table 9 below.
- Wnt signal-related gene group examples include the genes shown in Table 10 below.
- Examples of the signal transduction-related gene group include the genes shown in Table 11 below.
- Notch signal-related genes include the genes shown in Table 12 below.
- breast cancer and estrogen receptor signal-related genes include the genes shown in Table 13 below.
- colon cancer-related genes examples include the genes shown in Table 14 below.
- hypoxia signal-related gene group examples include the genes shown in Table 15 below.
- GPCR signal-related genes examples include the genes shown in Table 16 below.
- Examples of drug resistance-related genes include the genes shown in Table 17 below.
- Hedgehog signal-related gene group examples include the genes shown in Table 18 below.
- Examples of the PI3K-AKT signal-related gene group include the genes shown in Table 19 below.
- Examples of the drug metabolism gene group include the genes shown in Table 20 below.
- cancer molecular mechanism genes include the genes shown in Table 21 below.
- SMAD signal network-related genes examples include the genes shown in Table 22 below.
- pancreatic cancer-related genes examples include the genes shown in Table 23 below.
- prostate cancer-related genes include the genes shown in Table 24 below.
- liver cancer-related genes examples include the genes shown in Table 25 below.
- lung cancer-related gene group examples include the genes shown in Table 26 below.
- induced cancer stem cells of the present invention in addition to the endogenous cancer-related genes, stress and toxicity-related genes, epigenetics chromatin-modifying enzyme genes, stem cells It is preferable that at least one endogenous gene selected from the group of genes included in the group consisting of transcription factor genes has increased gene expression.
- Examples of stress and toxicity-related genes include the genes shown in Table 27 below.
- Examples of the epigenetics chromatin-modifying enzyme gene group include the genes shown in Table 28 below.
- stem cell transcription factor gene group examples include the genes shown in Table 29 below.
- At least one endogenous gene selected from the group consisting of genes included in the hepatocyte-specific gene group, Increased expression may occur.
- hepatocyte-specific genes include the following genes related to liver function. Since any of these genes may function as a gene related to the properties as cancer, in the induced cancer stem cell of the present invention, (b) in addition to the cancer-related gene, a hepatocyte-specific gene It is preferable that an increase in gene expression is observed in the group of genes.
- hepatocyte-specific gene group examples include the hepatocyte-related gene group (Hepa) described in Table 30 below.
- the table also illustrates GenBank accession numbers for each gene symbol, but the present invention is not limited by such description.
- induced cancer stem cells of the present invention it is preferable that genes characteristic of mesendoderm stem cells and endoderm stem cells are also expressed, and in particular, undifferentiated induced pluripotent stem cells serving as controls It is preferable that the expression is increased compared to the expression level of the gene.
- HiPS-201B7 is used as a target undifferentiated induced pluripotent stem cell.
- the gene expression data of this cell can be obtained from the Gene Expression Omnibus [GEO] described above.
- the gene characteristic of mesendoderm stem cells and endoderm stem cells is not particularly limited as long as it is a gene characteristic of each stem cell.
- examples of genes characteristic of mesendoderm stem cells include GSC genes
- examples of genes characteristic of endoderm stem cells include GSC gene, GATA4 gene, FOXA2 gene, SOX17 gene and the like. it can.
- the induced cancer stem cells of the present invention are easily induced to differentiate into cancer cells having the properties of specific tissue cells, they are induced to differentiate into cells that become cancerous in familial tumors, such as retinoblasts and intestinal epithelial cells. Can be induced in cancer cells such as retinoblastoma and colonic polyposis.
- the induced cancer stem cells of the present invention can be grown or subcultured for 3 days or longer, but are substantially self-in vitro capable of proliferating over a long period of one month or longer, half a year or longer than one year. It is a replicable induced cancer stem cell, which means that it can theoretically replicate indefinitely.
- the medium for proliferating culture or subculture of the induced cancer stem cells of the present invention is any medium that can proliferate or subculture embryonic stem cells, pluripotent stem cells, etc. Although not particularly limited, a medium suitable for culturing embryonic stem cells, pluripotent stem cells and the like is preferably used.
- ES medium [40% Dulbecco's modified Eagle medium (DMEM), 40% F12 medium (Sigma), 2 mM L-glutamine or GlutaMAX (Sigma), 1% Non-essential amino acids (Sigma), 0.1 mM ⁇ -mercaptoethanol (Sigma), 15-20% knockout serum replacement (Invitrogen), 10 ⁇ g / ml gentamicin (Invitrogen), 4-10 ng / ml FGF2 factor], ES medium excluding 0.1 mM ⁇ -mercaptoethanol, and conditioned medium which is a supernatant of mouse embryonic fibroblasts (hereinafter MEF) cultured for 24 hours, 0.1 mM ⁇ - Medium supplemented with mercaptoethanol and 10 ng / ml FGF2 (hereinafter MEF-conditioned ES medium), optimal medium for iPS cells (manufactured by Ipselon), optimal medium for feeder cells (manufactured by Ipselon), Ste
- the method of proliferating culture or subculture of the induced cancer stem cells of the present invention is not particularly limited as long as it is a method commonly used by those skilled in the art in culturing embryonic stem cells, pluripotent stem cells and the like.
- the medium is removed from the cells, washed with PBS ( ⁇ ), added with a cell detachment solution, allowed to stand, then the cell detachment solution is removed, and D-MEM (10% containing 1 ⁇ antibiotic-antimycotic agent and FBS) Add high glucose) medium, centrifuge, remove supernatant, add 1x antibiotic-antimycotic, mTeSR and Y-27632, and add cells to gelatin coat or collagen coat seeded with MEF
- a method of subculturing can be specifically exemplified by seeding the suspension.
- FGF2 bFGF
- the addition amount is preferably 1 to 100 ng / ml.
- FGF2 (bFGF) is selected according to the type of somatic cell to be induced.
- FGF2 (bFGF) derived from human, mouse, cow, horse, pig, zebrafish, etc. can be used.
- the above-described pituitary extract, serum, LIF, Z-VAD-FMK, ALK5 inhibitor, PD032591, CHIR00921, and the like can be added.
- Rho-related kinase (Rho-related coiled-coil-containing protein kinase) inhibitor Y-27632 (Calbiochem; water-soluble) or Fasudil (HA1077: Calbiochem) can also be added to the medium during passage.
- FGF receptor tyrosine kinase FGF receptor tyrosine kinase
- MEK mitogen activated protein kinase
- ERK extracellular signal regulated kinases 1 and 2 pathway
- GSK Glycogen Synthase Kinase
- Two small molecule inhibitors of the MEK / ERK pathway and GSK3 [PD0325901 and CHIR99021], a low molecular compound that is an inhibitor of histone methylase G9a [BIX-01294 (BIX)], azacitidine, trichostatin A (TSA) ), 7-hydroxyflavone, lysergic acid ethylamide, kenpaullone, TGF ⁇ GFreceptorI kinase / activin-like kinase 5 (ALK5) inhibitor [EMD 616452], TGF- ⁇ receptor 1 (TGFBR1)
- the induced cancer stem cells of the present invention can be frozen and thawed by a known method.
- a freezing method for example, the medium is removed from the cells, washed with PBS ( ⁇ ), added with a cell detachment solution, allowed to stand, then the cell detachment solution is removed, and 1 ⁇ antibiotic-antifungal agent and FBS 10%
- D-MEM high glucose
- removing the supernatant adding the freezing stock solution, dispensing into a serum tube, and freezing at ⁇ 80 ° C. overnight
- a method of storing in liquid nitrogen can be exemplified.
- the thawing method include a method of thawing in a constant temperature bath at 37 ° C. and suspending in a D-MEM (high glucose) medium containing 10% of 1 ⁇ antibiotic-antifungal agent and FBS. .
- This method is characterized in that an induction step is performed in which the raw somatic cells are placed in a state where the gene products of POU5F1 gene, KLF4 gene, and SOX2 gene are present in the raw somatic cells.
- the gene (1) self-replication-related gene
- the induced cancer stem cell of the present invention is induced.
- “put in a state” is a concept that includes not only the adjustment to such a state but also the selection and preparation of cells in such a state.
- somatic cells that are raw materials are (a) somatic cells collected from mammals having mutations in tumor suppressor genes, and A somatic cell collected from a mammal that has developed cancer, selected from the group consisting of somatic cells having either an abnormality of (a) mutation of a tumor suppressor gene or (b) increased expression of a cancer-related gene. It is necessary to be.
- the mammal from which the somatic cells are collected is not particularly limited as long as it is a mammal, and includes pigs such as rats, mice, guinea pigs, dogs, cats, minipigs, monkeys such as cattle, horses, cynomolgus monkeys, etc. Examples thereof include primates and humans, and rats, mice, guinea pigs, dogs, cats, minipigs, horses, cynomolgus monkeys, and humans are preferable, and humans are particularly preferable.
- the source somatic cells in the production method of the present invention must be non-embryonic cells, that is, cells derived from non-reproductive tissues. Accordingly, cells derived from reproductive tissues are not included in the raw somatic cells of the present invention.
- Such a non-embryonic source somatic cell is not particularly limited as long as it is a non-embryonic cell as described above, and somatic cells collected from mammal tissues at various times are used. be able to. Although it illustrates concretely below, it is not restrict
- umbilical cord tissue umbilical cord, umbilical cord blood
- amniotic membrane placenta
- amniotic fluid-derived cells and in particular, tissues immediately after birth (such as neonatal tissues)
- Umbilical cord tissue umbilical cord, umbilical cord blood
- tissue derived from skin and the like and blood vessels derived from the umbilical cord such as tissue derived from skin and the like and blood vessels derived from the umbilical cord.
- somatic cells collected from mammals having the mutation of the (a) tumor suppressor gene are not particularly limited as long as they have such abnormalities, and cause, for example, familial tumors. Somatic cells collected from mammals having a genetic abnormality can be used.
- Somatic cells collected from mammals having genetic abnormalities include somatic cells collected from mammals that have developed familial tumors, or somatic cells having genetic abnormalities that cause familial tumors in individuals related to the mammal Can be illustrated. These somatic cells are somatic cells (malignant cells) in both alleles even if they are somatic cells (precancerous cells) that have a genetic abnormality that causes familial tumors in one allele. May be.
- the induced precancerous stem cell of the present invention is induced, and when the malignant cell is used, the induced malignant stem cell of the present invention is induced.
- somatic cells having a genetic abnormality in the one-sided allele include somatic cells collected from other than carcinogenic tissues of mammals that have developed familial tumors, and genetic abnormalities that cause familial tumors in individuals related to the mammals. Somatic cells (pre-cancerous cells) having On the other hand, as a somatic cell (malignant cell) having a genetic mutation in both alleles, a mammalian cancer cell that has developed a familial tumor can be exemplified.
- cells of cancer tissue substantially consisting of cancer cells are preferably used.
- cells of non-cancerous tissue containing cancer cells can also be used.
- endoderm-derived induced cancer stem cells of the present invention there is no particular limitation on the germ layers from which the somatic cells used when producing the induced cancer stem cells of the present invention are produced.
- endoderm-derived induced cancer stem cells of the present invention endoderm cells, somatic cells derived from the liver, stomach, large intestine, colon, etc. can be used as raw material somatic cells, Somatic cells derived from the stomach or colon are preferably used.
- a somatic cancer cell collected from a carcinogenic mammal may be used as a raw material somatic cell used in the production method of the present invention.
- a somatic cancer cell collected from a carcinogenic mammal.
- Such a cell is a cell having abnormalities such as (a) mutation of a tumor suppressor gene, abnormal gene expression, etc. peculiar to cancer cells.
- These somatic cells are collected from cancerous tissue containing cancer cells and precancerous cells of a mammal that has developed cancer or from non-cancerous tissue containing cancerous cells and precancerous cells. It is actually difficult to collect only cancer cells.
- the finally obtained induced cancer stem cells of the present invention were: (a) cancer It can be confirmed by clarifying whether or not there are abnormalities such as mutations in suppressor genes and abnormal gene expression (however, germline mutations can be distinguished even in the source cells). This is because, when the finally obtained induced cancer stem cell of the present invention has abnormalities such as (a) mutation of a tumor suppressor gene and increased gene expression, these abnormalities are It is because it is recognized that it inherited the abnormality which a cell has.
- the origin of the somatic cells is not particularly limited.
- somatic cells collected from a mammal that has developed carcinogenesis the following somatic cells can be used.
- mesendoderm and endoderm somatic cells can be used, respectively. Therefore, somatic cells collected from the liver, stomach, duodenum, small intestine, large intestine, colon, pancreas, lung, etc. can be induced into induced mesendoderm malignant stem cells or induced endoderm malignant stem cells.
- cancer there are no particular restrictions on the type of cancer that has occurred in the mammal, and any type of malignant tumor, solid cancer, cancer type, sarcoma, brain tumor, hematopoietic cancer, leukemia, lymphoma, multiple myeloma, etc. It may be cancer.
- oral cancer pharyngeal cancer, upper respiratory tract cancer, lung cancer, lung cell cancer, esophageal cancer, stomach cancer, duodenal cancer, pancreatic cancer, liver cancer, gallbladder cancer, biliary tract Cancer, colon cancer, colon cancer, rectal cancer, breast cancer, thyroid cancer, endometrial cancer, cervical cancer, ovarian cancer, testicular cancer, kidney cancer, bladder cancer, prostate cancer, skin
- malignant melanoma brain tumor, osteosarcoma, blood cancer and the like.
- the raw somatic cells used in the production method of the present invention can be used immediately after being collected from a mammal, or can be used after being stored and cultured by a known method. In the case of culturing, the number of passages is not particularly limited. Table 31 shows the GenBank accession numbers for the POU5F1, KLF4, and SOX2 gene symbols.
- the raw somatic cell is in a state where the gene product of the POU5F1 gene, the KLF4 gene, and the SOX2 gene is present in the raw somatic cell.
- the method include, but are not limited to, a known method as a technique for inducing induced pluripotent stem cells.
- the POU5F1, KLF4 gene, and SOX2 gene gene products are in a specific ratio at the time of induction from the somatic cell to the induced cancer stem cell of the present invention.
- the desired induced cancer stem cells can also be produced by adjusting to exist in the cells.
- the abundance ratio of the POU5F1 gene, the KLF4 gene, and the SOX2 gene in the source somatic cell is POU5F1 gene> SOX2 gene, stomach, large intestine, liver, lung, pancreas, etc. Induced cancer stem cells of the endoderm system are induced.
- POU5F1 gene> KLF4 gene> SOX2 gene when inducing endoderm-derived induced cancer stem cells, it is preferable that POU5F1 gene> KLF4 gene> SOX2 gene, and the desired induced cancer stem cells of the present invention are induced with high efficiency. It is preferable from the viewpoint. Among them, the use ratio of the POU5F1 gene, the KLF4 gene, and the SOX2 gene is preferably 4: 2: 1. Takahashi et al. (Takahashi K, Yamanaka S et al., Cell, 2007, 131, 861-872; Non-Patent Document 3) and Masaki et al.
- each gene is used in an equal amount, that is, 1: 1: 1.
- Kyoto University iPS Information on the use of an equal amount of the gene is also provided by the Cell Laboratory.
- the POU5F1, KLF4, and SOX2 genes themselves can be used as genes that can increase the expression intensity of the POU5F1, KLF4, and SOX2 genes.
- the expression of the POU5F1 gene, the KLF4 gene or the SOX2 gene in the raw material cell is insufficient, the gene or gene product that is deficient in the cell is introduced, and the POU5F1 gene, the KLF4 gene in the cell
- the SOX2 gene when the SOX2 gene is expressed, other genes or gene products thereof may be introduced instead of the POU5F1, KLF4, and SOX2 genes.
- induced pluripotent stem cells such as NANOG gene, LIN28 gene, TBX3 gene, if they are already expressing POU5F1 gene, KLF4 gene, or SOX2 gene , PRDM14 gene, L-MYC gene, c-MYC gene, N-MYC gene, SALL1 gene, SALL4 gene, UTF1 gene, ESRRB gene, NR5A2 gene, REM2 GTPase gene, TCL-1A gene, Yes-associated protein (YAP) It is also possible to introduce the induced cancer stem cells of the present invention by introducing a gene, E-cadherin gene, p53 dominant negative mutant gene, p53 shRNA gene, and the like.
- GenBank accession numbers for the NANOG gene, LIN28 gene, TBX3 gene, and c-MYC gene symbol are as described in Table 32.
- the chromatin structure of the self-replication-related genes group is changed, and the POU5F1 gene, the KLF4 gene and the The SOX2 gene product is thought to induce self-replication as a result of inducing the expression of endogenous self-replication-related genes.
- induced pluripotent stem cells As a method for introducing the POU5F1 gene, the KLF4 gene and the SOX2 gene, and proteins and mRNAs, which are gene products of genes used in place of these genes, into the source somatic cells, induced pluripotent stem cells
- the induction technique include known methods, but are not limited thereto.
- protein, mRNA, etc. which are gene products of these genes, may be added to the medium.
- induced pluripotent stem cells such as FGFMEreceptor tyrosine kinase, MEK (mitogen activated protein kinase ) / ERK (extracellular signal regulated kinases 1 and 2) pathway, three small molecule inhibitors of GSK (Glycogen Synthase Kinase) 3 [SU5402, PD184352 and CHIR99021], MEK / ERK pathway and two small molecule inhibitors of GSK3 [ PD0325901 and CHIR99021], low molecular weight compounds that are inhibitors of histone methyltransferase G9a [BIX-01294 (BIX)], azacitidine, trichostatin A (TSA), 7-hydroxyflavone, lysergic acid ethylamide, kenpaullone, TGF ⁇ receptorI kinase / inhibitors of activin
- FGFMEreceptor tyrosine kinase MEK (mitogen activated
- a method for introducing a gene into the mammalian cell is not particularly limited as long as it is a known method, but a viral vector, Plasmids, artificial chromosomes (HAC), episomal vectors (EBV), minicircle vectors, polycistronic expression vectors, vectors using the Cre / loxP system, vectors using phage integrase, vectors such as piggybacks and other transposons Etc. can be used.
- any known viral vector can be used as a viral vector that can be used to introduce a gene into the somatic cell.
- the retroviral vector includes a Moloney murine leukemia virus-derived retroviral vector.
- any known viral vector plasmid can be used as the viral vector plasmid.
- pMXs, pMXs-IB, pMXs-puro, pMXs-neo as retrovirus systems
- pMXs-IB is a vector carrying a blasticidin resistance gene instead of the puromycin resistance gene of pMXs-puro
- pMXs-IB is a vector carrying a blasticidin resistance gene instead of the puromycin resistance gene of pMXs-puro
- MFG Proc. Natl. Acad . Sci.
- pAdex1 Nucleic Acids Res., 23, 3816-3821 (1995)] etc. can be used as an adenovirus system.
- the production method of the present invention can further include a step of sorting and proliferating one cell in one well.
- This step consists of anti-ALB antibody, anti-FABP1 antibody, anti-IGF-II antibody, anti-DLK1 antibody, anti-PDGFR ⁇ antibody, anti-VEGFR2 antibody, anti-E-cadherin antibody, anti-CXCR4 antibody, anti-PDGFR ⁇ antibody, anti-cadherin 11 antibody, anti-cadherin 11 antibody, In the step of proliferating cells stained with specific antibody using any one antibody selected from CD34 antibody and anti-IGF-R1 antibody, or unstained cells by a method of sorting one cell in one well is there.
- the induced cancer stem cells of the present invention are stained with a specific antibody such as E-cadherin as described above, and then the specific antibody is used at 1 cell / well using PERFLOW TM Sort (Furukawa Electric).
- PERFLOW TM Sort Fluukawa Electric
- a method of single sorting the stained cells into a 96-well plate or the like is mentioned. It is also possible to use unstained cells instead of cells stained with special antibodies.
- the production method of the present invention may further include a selection step of identifying and selecting a malignant property or specific marker of induced cancer stem cells capable of self-replication in vitro.
- malignant properties refer to properties related to infinite proliferation ability, invasion, metastasis, resistance, recurrence, etc. of cancer cells.
- the specific marker refers to a property capable of identifying cancer cells such as a protein (secreted protein or the like) or a specific protein or sugar chain antigen on the surface of the cancer cell.
- a specific marker for example, (b) increased expression of a cancer-related gene can be used.
- Cancer-related genes include angiogenesis-related genes, cancer-related pathway genes, stromal barrier-related genes, epithelial-mesenchymal transition related genes, gastric cancer-related genes, autonomous growth-related genes, TGF ⁇ / BMP signal related genes, tissue invasion / metastasis related genes, Wnt signal related genes, signal transduction related genes, Notch signal related genes, breast cancer and estrogen receptor signal related genes, colon cancer related genes Group, hypoxia signal related gene group, GPCR signal related gene group, drug resistance related gene group, Hedgehog signal related gene group, PI3K-AKT signal related gene group, drug metabolism gene group, cancer molecular mechanism gene group, SMAD signal network Related gene group, Pancreatic cancer related gene group, Prostate cancer related gene group, Liver cancer related gene group, Lung cancer related genetics An increase in the expression of endogenous cancer-related genes related to the offspring group can be mentioned.
- the selection step includes (a) somatic cells collected from a mammal having a cancer suppressor gene mutation, and (a) a cancer suppressor gene mutation, or (b) a cancer collected from a mammal that has developed carcinogenesis.
- Induced from non-embryonic source somatic cells selected from the group consisting of somatic cells with any abnormalities in the expression of related genes and somatic cells collected from mammals to be compared It may be a step of comparing induced mesendoderm stem cells, induced endoderm stem cells, induced pluripotent stem cells, or embryonic stem cells.
- the somatic cell collected from the mammal to be compared is not particularly limited as long as it is a somatic cell collected from each tissue of the mammal at various times.
- mammalian tissues include various tissues exemplified as tissues used as source somatic cells for producing the above-described induced cancer stem cells of the present invention.
- the somatic cell collected from the mammal to be compared is not particularly limited as long as it is a normal cell or a non-cancer cell having no abnormality as the raw material somatic cell of the present invention.
- -Derived somatic cells neonatal-derived somatic cells, neonatal skin-derived somatic cells, carcinogenic mammalian somatic cells that are substantially non-cancerous or carcinogenic as the source somatic cells of the present invention
- Individual somatic cells can be used.
- adult-derived somatic cells, neonatal-derived somatic cells, and neonatal skin-derived somatic cells that are considered to have few abnormalities in the raw somatic cells of the present invention can be used.
- cancer cells of a carcinogenic mammal When cancer cells of a carcinogenic mammal are used as the source somatic cells, normal cells or non-cancer cells of the same individual as the carcinating mammal are used as somatic cells collected from the mammal to be compared. Can be used. In particular, when cells collected from the same organ of the same individual are used, since the characteristics unique to the individual or the organ are common, the difference in malignancy between both cells becomes clear. Therefore, the process of comparing the tissue of the same individual as the individual from which such source somatic cells were collected not only identifies the malignant nature or specific markers of induced cancer stem cells, but also an analysis tool such as elucidation of the carcinogenic mechanism It is also useful as a drug discovery target screening method described later.
- the mammal from which the somatic cell to be compared is collected may be the same as the mammal from which the somatic cell is collected, and is particularly preferably a human.
- induced mesendoderm stem cells derived from somatic cells collected from mammals to be compared and induced endoderm stem cells are those derived from somatic cells collected from the mammals to be compared. If it is, it will not restrict
- the induced pluripotent stem cells derived from somatic cells collected from the mammals to be compared are not particularly limited as long as they are prepared by a known induced pluripotent stem cell induction method. Those obtained by induction by the same method as the method for inducing induced cancer stem cells of the present invention are preferably used. In addition, it was induced by the methods described in Patent Documents 1 and 2 and "Method of establishing human iPS cells", Kyoto University, Center for Materials-Cell Integrated Systems, iPS Cell Research Center, CiRA / M & M, p1-14, 2008.7.4.
- Induced pluripotent stem cells Induced pluripotent stem cells that can be obtained from known routes such as RIKEN BioResource Center and Kyoto University, and well-known pluripotent stem cells derived from Gene ⁇ Expression ⁇ ⁇ Omnibus [GEO] Etc. can also be used.
- embryonic stem cells can be used, and any of those prepared by a known method can be used.
- Thomson JA et al. "Embryonic stem cell lines derived from human blastocysts.”. Science.1998 Nov 6; 282 (5391): 1145-7. Erratum in: Science 1998 Dec 4; 282 (5395): 1827.
- Hirofumi Suemori et al. "Efficient establishment of human embryonic stem cell lines and long term maintenance with stable karyotype by enzymatic bulk passage.”, Described in Biochemical andphyBiophysical Research Communications, 345, (926-32 Undifferentiated embryonic stem cells, undifferentiated embryonic stem cells available from publicly known routes such as RIKEN BioResource Center, Institute of Regenerative Medicine, Kyoto University, hES_H9 (GSM194390), hES_BG03 (GSM194391), hES_ES01 (GSM194392) It is also possible to use known gene expression data such as These gene expression data can be obtained from the above-described Gene® Expression® Omnibus [GEO].
- the induced cancer stem cells of the present invention are selected as the induced cancer stem cells of the present invention when (a) a mutation is confirmed and identified in the tumor suppressor gene. In the present invention, (a) it suffices if mutations are confirmed in the tumor suppressor gene, and it is not always necessary to analyze all genomes.
- the induced cancer stem cell of the present invention is identified and identified as (c) an increased expression of a cancer-related gene as compared with the cell to be compared, it is selected as the induced cancer stem cell of the present invention. It is possible.
- Transcriptome analysis refers to all mRNAs (or primary transcripts, transcripts, etc.) present in a single or proliferated, similarly differentiated organism cell under certain cell biology conditions. ). Since mRNA changes in various ways due to the accumulation of extraneous effects that the cells have received during development, it is possible to analyze the current cellular properties in detail. Specifically, the analysis is performed using a microarray or the like.
- the induced cancer stem cell of the present invention contains (a) more mRNA corresponding to a mutated tumor suppressor gene and (b) more mRNA for a cancer-related gene than the cell to be compared.
- cancer-related genes for example, angiogenesis-related genes, cancer-related pathway genes, Stromal barrier related gene group, epithelial-mesenchymal transition related gene group, gastric cancer related gene group, autonomous proliferation related gene group, TGF ⁇ / BMP signal related gene group, tissue invasion / metastasis related gene group, Wnt signal related gene group, Signal transduction related gene group, Notch signal related gene group, breast cancer and estrogen receptor signal related gene group, colon cancer related gene group, hypoxia signal related gene group, GPCR signal related gene group, drug resistance related gene group, Hedgehog signal Related gene group, PI3K-AKT signal related gene group, drug metabolism gene group, cancer molecular mechanism gene , At least selected from the group of genes included in the group consisting of SMAD signal network-related genes, pancreatic cancer-related genes, prostate cancer-related genes, liver cancer-related genes, and lung cancer-related genes A specific
- genes selected from the group of genes included in the group consisting of stress and toxicity-related genes, epigenetics chromatin-modifying enzyme genes, stem cell transcription factor genes, hepatocyte-specific genes, It is preferable to make a comprehensive judgment based on an increase in the expression of a gene related to at least one kind of gene.
- the screening method is characterized by using the induced cancer stem cells of the present invention. It is suitable as a screening method and a screening method for a cancer diagnostic agent.
- the screening method of the present invention comprises an induced mesendoderm stem cell, an induced endoderm stem cell or an induced pluripotent stem cell derived from the induced cancer stem cell of the present invention and a somatic cell collected from a mammal to be compared, Alternatively, it is preferable to include a step of bringing a test substance into contact with each embryonic stem cell.
- induced mesendoderm stem cells, induced endoderm stem cells or induced pluripotency derived from the induced cancer stem cells of the present invention and somatic cells collected from a mammal to be compared
- somatic cells collected from a mammal By comparing with sex stem cells or embryonic stem cells, it is possible to search for genes and proteins that can be cancer drug targets.
- the induced cancer stem cells of the present invention were cultured with a specific inhibitor of antisense RNA, siRNA, or a translation protein (such as an enzyme) of the gene that suppresses the expression of a gene presumed to be a drug discovery target. It is possible to evaluate whether or not it can be a drug discovery target by adding it to a petri dish and confirming the properties of the cells after the addition.
- drugs that are candidates for anticancer drugs and vaccines are added to the petri dish in which the induced cancer stem cells of the present invention are cultured, and the properties of the cells are evaluated. By doing, medicinal effect can be confirmed.
- various types of the induced cancer stem cells of the present invention are added to the cancer diagnostic agent, and it is confirmed whether or not the cancer is accurately diagnosed. It is possible to evaluate whether it is effective as a medicine.
- a cancer vaccine useful for CTL therapy, dendritic cell therapy, cancer peptide vaccine therapy and the like can be produced using the induced cancer stem cells of the present invention.
- CTL therapy Cytotoxic T-lymphocyte Therapy: Cytotoxic T lymphocyte therapy
- CTL cells cytotoxic T lymphocytes
- CTL therapy there are a method using an antigen of a patient's own cancer cell and a method using an artificial antigen to learn lymphocytes. Is said to be more effective.
- a method using an antigen of a patient's own cancer cell Is said to be more effective.
- it is difficult to culture there is a problem that a relatively large tumor is removed by surgery and the antigen is successfully extracted.
- the induced cancer stem cells of the present invention are capable of self-replication in vitro, it is possible to prepare a necessary amount of induced cancer stem cells, and in addition, the body of a cancer patient by collecting cancer cells. This is very useful because it can reduce the burden on the user.
- More specific production methods include, for example, extracting T cells that can attack cancer cells from a patient's blood, such as by collecting blood from the component, and the induced cancer stem cells of the present invention, lysates obtained by dissolving these cells, Adds a cancer antigen protein or peptide obtained based on these cells to allow T cells to learn the cancer antigen. Next, after activating with anti-CD3 antibody or the like, culturing with interleukin 2 or the like yields a large amount of T lymphocytes having cytotoxicity as cancer vaccines.
- induced cancer stem cells or lysates in which these cells are dissolved are used as cancer antigens, they are collected from cancer tissues surgically removed from patients undergoing treatment or ascites of the patients. Those prepared from cancer cells are preferably used.
- Dendritic cell therapy is a treatment method in which the dendritic cells collected from the patient learn the characteristics of the cancer to be attacked, and the dendritic cells are returned to the patient's body. Cells stimulate T lymphocytes, and the stimulated T cells become killer T cells to treat cancer by attacking cancer cells.
- this treatment method has a problem that it is limited to the case where a relatively large tumor is removed by surgery and the antigen is successfully extracted, and the induced cancer stem cell of the present invention is in vitro. Because it can self-replicate, it is possible to prepare the necessary amount of induced cancer stem cells, and in addition, it can reduce the physical burden on cancer patients due to the collection of cancer cells. Useful.
- More specific production methods include, for example, induced cancer stem cells, lysates obtained by dissolving these cells in dendritic cells extracted by component blood collection, and further obtained based on these cells.
- a dendritic cell is made to learn the cancer antigen, and a dendritic cell that is a cancer vaccine is produced.
- induced cancer stem cells or lysates in which these cells are dissolved as cancer antigens cancer cells extracted by surgery from patients undergoing treatment, cancer cells collected from ascites of the patients, etc. Those prepared from the above are preferably used.
- the dendritic cells described above can stimulate hundreds to thousands of lymphocytes with a single dendritic cell, the dendritic cells learn the characteristics of cancer and return to the body. Considered to be very efficient. However, since the number of dendritic cells is about 0.1 to 0.5% of leukocytes, a large amount of monocytes that can be transformed into dendritic cells, which are present in the blood, are obtained in large quantities by the component separation blood sampling method. It is possible to cultivate the monocytes into dendritic cells using a substance that stimulates cells, and use them.
- Cancer peptide vaccine therapy is a treatment method that suppresses an increase in cancer by injecting a peptide (peptide vaccine) as a specific antigen possessed by cancer cells to enhance the immunity of the patient. Specifically, when this peptide (a small peptide with 9 or 10 amino acids linked) is administered into the body, killer T cells stimulated by the peptide are activated and proliferate to attack cancer cells. It is a treatment method that eliminates (regresses) cancer using the property of becoming.
- the induced cancer stem cells of the present invention can be self-replicated in vitro and can be used to amplify various induced cancer stem cells in large quantities. Therefore, the induced cancer stem cells are prepared from cancer tissues derived from various cancer patients. In addition, it is possible to produce a target cancer vaccine by culturing a large amount of the induced cancer stem cells of the present invention. The cancer vaccine thus obtained can also be used for CTL therapy or dendritic cell therapy.
- the cancer vaccine as described above is very effective in preventing recurrence after standard therapies such as preventive treatment of cancer, chemotherapy, radiation therapy, and surgical therapy.
- a gall cancer mouse can be prepared by transplanting the induced cancer stem cell of the present invention to a laboratory animal such as a mouse. After administering an anticancer agent, antibody, vaccine or the like to the bile cancer mouse, the drug effect can be confirmed by performing a blood test, a urine test, an autopsy or the like of the bile cancer mouse.
- the induced cancer stem cells of the present invention can be applied in various ways other than the screening method, cancer vaccine preparation method, and cancer model animal preparation method described above.
- the secretory protein and membrane protein are comprehensively screened from the genetic information of the induced cancer stem cell, and the membrane protein and secretory protein specific to the induced cancer stem cell of the present invention useful as a cancer diagnostic marker are identified.
- therapeutic or diagnostic antibodies can be produced.
- a “signal sequence strap method” characterized by gene identification targeting a signal sequence that is commonly present in membrane proteins and secreted proteins (Japanese Patent No. 3229590 and Patent No. 3499528).
- Retroviral Vector Pantropic retrovirus was prepared using Fugene HD (Roche; Cat no. 4709691) using a retroviral vector plasmid of three genes POU5F1-pMXs, KLF4-pMXs, and SOX2-pMXs. It was introduced into Plat-GP cells, which are packaging cells for vector preparation, and a retroviral vector solution was prepared.
- the genes POU5F1-pMXs, KLF4-pMXs, and SOX2-pMXs were used in a ratio of 4: 2: 1 in this order so that POU5F1> SOX2. Details are as follows.
- the amount of each vector is POU5F1-pMXs MX5 ⁇ g, KLF4-pMXs 2.5 ⁇ g, SOX2-pMXs 1.25 ⁇ g, Venus-pCS2 1.25 ⁇ g, VSV-G-pCMVp5 ⁇ g, GFP-pMXs1.25 ⁇ g (manufactured by Cell Biolab), FuGENE HD45 ⁇ l did.
- the amount of each vector was POU5F1-pMXs 5 ⁇ g, KLF4-pMXs 2.5 ⁇ g, SOX2-pMXs 1.25 ⁇ g, Venus-pCS2 1.25 ⁇ g, VSV-G-pCMV 5 ⁇ g, GFP-pMXs 1.25 ⁇ g, FuGENE HD 43 ⁇ l.
- the amount of each vector was POU5F1-pMXs 5 ⁇ g, KLF4-pMXs 2.5 ⁇ g, SOX2-pMXs 1.25 ⁇ g, Venus-pCS2 1.25 ⁇ g, VSV-G-pCMV 5 ⁇ g, GFP-pMXs 1.25 ⁇ g, FuGENE HD 43 ⁇ l.
- the Plat-GP cells into which the retroviral vector plasmid had been introduced were cultured for 48 hours or longer, and then the supernatant was collected 3 times every 24 hours and stored at 4 ° C.
- Steriflip-HV filter unit Filtration was performed with a 0.45 ⁇ m filter (Millipore; Cat no.SE1M003M00).
- the pantropic retrovirus vector solution of 3 genes (POU5F1, KLF4, SOX2 ratio in order 4: 2: 1) was prepared by the above procedure.
- Pantropic retroviral vectors can introduce genes into various cells, and can introduce genes into human cells with high efficiency.
- Example 2 Preparation of Induced Malignant Stem Cells from Cancer Tissue-Derived Cells of Gastric Cancer Patients
- Somatic cells were isolated from fresh cancer tissues of human gastric cancer (advanced cancer) patients that were stored and transported in a preservation solution for several hours.
- 3 cells POU5F1, KLF4, SOX2 ratio in order 4: 2: 1) retrovirus vector solution satisfying the relationship of POU5F1>KLF4> SOX2 prepared in Example 1 to the cells derived from the cancer tissue of the stomach cancer patient obtained was added, and gene induction was performed to prepare human induced malignant stem cells. Details are as follows.
- a portion of fresh gastric cancer tissue obtained at the time of surgery was washed with Hank's equilibration solution (without phenol red) (Invitrogen; Cat no.14175-095). Then, it was chopped to about 0.1-1 mm 2 using a scissors. Further, the supernatant was washed with Hank's equilibration solution (without phenol red) until the supernatant became clear, the supernatant was removed, and 5 ml of 0.1% collagenase (Wako Pure Chemical Industries; Cat no.034) was added to the tissue precipitate. -10533) / 1 ⁇ antibiotic-antimycotic agent was added and stirred at 37 ° C. for 60 minutes using a shaker.
- D-MEM high glucose medium containing 10% of 1 ⁇ antibiotic-antimycotic agent and FBS was added, and collagen-coated dish 60 mm (made by Iwaki; Cat no.11) -018-004) and primary culture.
- D-MEM high glucose
- the MEF-conditioned ES medium was continuously replaced every 3 days, and the medium was changed daily with the feeder cell-free human ES / iPS cell medium mTeSR 15 days after the gene transfer.
- the MEF-conditioned ES medium used throughout the examples and the preparation method thereof are as follows.
- MEM non-essential amino acid solution (Invitrogen; Cat no.11140-050) 10 ng / ml bFGF (manufactured by Peprotech; Cat no.100-18B)
- ⁇ Preparation of MEF-conditioned ES medium> Mouse embryonic fibroblasts treated with mitomycin (DS Pharma Biomedical; Cat no. R-PMEF-CF) 5 ⁇ 10 6 cells, 1 ⁇ antibiotic-antifungal and 10% FBS D After being suspended in 40 ml of -MEM (high glucose) medium, it was seeded on 4 sheets of gelatin coated dish 100 mm (manufactured by Iwaki; Cat no. 11-020-006). After 24 hours, the medium was removed, and 10 ml of ES medium for acclimation of MEF was added.
- GC1-1 then subcultured human induced malignant stem cells (first passage) grown in 24-well plates 32 days after gene transfer to 6-well plates (second passage). 43 days after gene transfer, human induced malignant stem cells (second passage) grown in 6-well plates were passaged (10th passage) to a 10 cm culture dish. 50 days after gene transfer, human induced malignant stem cells (3rd passage) grown in 10 cm culture dishes were subcultured (passage 4) and cryopreserved in 10 cm culture dishes. 55 days after the gene transfer, human induced malignant stem cells (4th passage) grown in 10 cm culture dishes were passaged (5th passage) and cryopreserved in 10 cm culture dishes.
- the cell cryopreservation performed in the examples of the present invention is as follows.
- GC1-5 Days after gene transfer 44 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 52: 6-well plate (2nd passage) ⁇ 10 cm (3rd passage) Number of days after gene transfer 61: Passage and preservation (passage 4) Days after gene transfer 63: Storage and buffer RLT (cell lysate before RNA purification) treatment.
- GC1-7 Days after gene transfer 44 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 52: 6-well plate (2nd passage) ⁇ 10 cm (3rd passage) Number of days after gene transfer 61: Passage and preservation (passage 4) Days after gene transfer 62: Storage and buffer RLT (cell lysate before RNA purification) treatment.
- induced malignant stem cells derived from cancer tissues of gastric cancer patients were self-replicated in vitro using METe as feeder cells and mTeSR1 medium for human ES / iPS cells for free of feeder cells.
- Example 3 Preparation of human-derived malignant stem cells from cells derived from non-cancerous tissue of a stomach cancer patient Isolate cells from fresh non-cancerous tissue of a human gastric cancer (advanced cancer) patient stored and transported in a preservation solution for several hours, Primary culture was performed. Add the 3 genes prepared in Example 1 (POU5F1, KLF4, SOX2 ratio in order 4: 2: 1) retroviral vector solution to the cells derived from the non-cancerous tissue of the stomach cancer patient and introduce the gene. Thus, human induced malignant stem cells were prepared. Details are as follows.
- D-MEM high glucose medium containing 10% of 1 ⁇ antibiotic-antimycotic agent and FBS was added, and collagen-coated dish 100 mm (made by Iwaki, Cat ⁇ no.11) -018-006).
- the following shows the days (days after gene transfer) when cells related to human-derived malignant stem cells derived from non-cancerous tissues of stomach cancer patients were dissolved in the passage (p) and buffer (RLT buffer) for RNA recovery kit.
- NGC1-1 Days after gene transfer 52 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 58: 6-well plate (2nd passage) ⁇ 10 cm (3rd passage) 65 days after gene transfer: Passage, storage, buffer RLT (cell lysate before RNA purification) treatment.
- induced malignant stem cells derived from a non-cancer tissue of a stomach cancer patient were self-replicated in vitro using the feeder cell-free human ES / iPS cell culture medium mTeSR1 together with MEF as feeder cells.
- Example 4 Preparation of Human-Induced Malignant Stem Cells from Cells Derived from Cancer Tissues of Colon Cancer Patients
- Cells were isolated from fresh cancer tissues of human colon cancer patients that had been stored and transported in a preservation solution for several hours.
- To the cells derived from fresh cancer tissue of the obtained human colon cancer patient add the 3 genes prepared in Example 1 (POU5F1, KLF4, SOX2 ratio in order 4: 2: 1) retroviral vector solution, By introducing the gene, human induced malignant stem cells were prepared. Details are as follows.
- a portion of colon cancer (sigmoid colon cancer: male, 55 years old, Japanese) obtained at the time of surgery was washed with Hank's equilibration solution (without phenol red), and approximately 0.1-1 mm 2 using a scissors Shredded into The supernatant was washed with Hanks equilibration solution (no phenol red) until the supernatant became clear. Subsequently, the supernatant was removed, 5 ml 0.1% collagenase / 1 ⁇ antibiotic-antifungal agent was added to the tissue precipitate, and the mixture was stirred at 37 ° C. for 60 minutes using a shaker.
- D-MEM high glucose medium containing 10% of 1 ⁇ antibiotic-antimycotic agent and FBS was added, and collagen-coated dish 100 mm (made by Iwaki, Cat11no.11-018) -006).
- CC1-10 shows the passage of human-derived malignant stem cells derived from cancer tissue of colon cancer patients (p) and the day of dissolution (buffer RLT) of RNA recovery kit (number of days after gene transfer) Number of days after gene transfer 49: 24 wells (1st passage) ⁇ 6 wells (2nd passage) Days after gene transfer 54: 6 wells (2nd passage) ⁇ 10 cm (3rd passage) 59 days after gene transfer: Passage and preservation (passage 4) Days after gene transfer 63: Passage and preservation (5th passage) 68 days after gene transfer: Partial treatment with buffer RLT (cell lysate before RNA purification) 71 days after gene transfer: Qiazol (cell lysis solution before RNA purification) treatment 75 days after gene introduction Transplanted into NOD-SCID mice.
- buffer RLT cell lysate before RNA purification
- Qiazol cell lysis solution before RNA purification
- induced malignant stem cells derived from cancer tissue of colon cancer patients were self-replicated in vitro using MEF as feeder cells and mTeSR1 medium for human ES / iPS cells for free of feeder cells.
- Example 5 Quantitative analysis by microarray Genome-wide gene expression (mRNA transcriptome) was analyzed by Agilent Whole Human Genome Oligo DNA Microarray (4X44K). The microarray data of three types of human embryonic stem cells hES_H9 (GSM194390), hES_BG03 (GSM194391) and hES_ES01 (GSM194392) and induced pluripotent stem cells hiPS-201B7 (GSM241846) were downloaded from GEO and used.
- RNA and genomic DNA Buffer the total RNA and genomic DNA of human-derived malignant stem cells (GC1-1, GC1-3, GC1-5, GC1-7, GC1-8, NGC1-1, CC1-10) of Examples 2 to 4 in advance. Extraction was performed from the solution treated with RLT (cell lysate before RNA purification) using AllPrep DNA / RNA Mini Kit (50) (Qiagen; Cat no. 80204).
- RNA quality check When RNA was checked for quality with Agilent 2100 Bioanalyzer (Agilent) using LabChip for RNA (registered trademark of Agilent), the quality of all RNA samples was checked. Was good. In addition, when the RNA concentration and RNA purity were evaluated using NanoDrop ND-1000 (NanoDrop Technologies), it was confirmed that there was a total RNA amount necessary for cRNA synthesis in all samples, and that the purity was also high. It was done.
- the median value of the entire gene expression distribution (the fluorescence value distribution of each probe) was expressed as 0. A probe showing a value exceeding 0 was regarded as a probe in which gene expression was detected, and gene expression was determined to be present.
- human induced malignant stem cells (GC1-1, GC1-3, GC1-5, GC1-7, GC1-8, NGC1-1, CC1-10) are compared with human induced pluripotent stem cells (hiPS201B7) As a result, expression of the endoderm genes GSC gene, GATA4 gene, FOXA2 gene or SOX17 gene was increased.
- human induced malignant stem cells are GSCs, which are endoderm genes compared to human induced pluripotent stem cells (hiPS201B7) and human embryonic stem cells.
- the expression of the gene and GATA4 gene, FOXA2 gene or SOX17 gene was increased more than 2-fold.
- the human induced endoderm malignant stem cells GC1-5 of the present invention are human embryonic stem cells hES_BG03.
- Table 34 [hES_BG03 vs GC1-5] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased more than 2-fold compared to (GSM194391). Furthermore, the figure which plotted the probe of the angiogenesis related gene whose expression is more than 2 times increased is shown (FIG. 1).
- GC1-5 is a human-derived malignant stem cell derived from primary cultured (non-embryonic) cells prepared from fresh cancer tissue (stomach cancer tissue) of cancer patients, and is an angiogenesis-related gene that is an endogenous cancer-related gene. It was revealed that (MDK gene, TIMP2 gene, FGFR3 gene, PLAU gene, ID3 gene) are relatively highly expressed.
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic.
- Table 35 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers and probes of genes whose expression is more than doubled compared to stem cells hES_H9 (GSM194390) and human induced pluripotent stem cells hiPS-201B7.
- Table 36 [hiPS-201B7 vs NGC1-1], respectively.
- NGC1-1 is a human-derived malignant stem cell derived from primary cultured (non-embryonic) cells prepared from fresh non-cancerous tissue (stomach non-cancerous tissue) of cancer patients and is an endogenous cancer-related pathway gene (MMP2 gene, TIMP1 gene, TIMP3 gene, MMP1 gene, CDKN1A gene, S100A4 gene) were found to be relatively highly expressed.
- MMP2 gene, TIMP1 gene, TIMP3 gene, MMP1 gene, CDKN1A gene, S100A4 gene were found to be relatively highly expressed.
- stromal barrier-related genes Among the probes of stromal barrier-related genes mounted on Agilent's Whole Human Genome oligo DNA microarray (4X44K), the human induced endoderm malignant of the present invention
- the gene symbols, GenBank accession numbers, and probes of genes whose stem cells GC1-5 are more than twice as expressed as human embryonic stem cells hES_BG03 (GSM194391) are listed in Table 37 below [hES_BG03 vs GC1-5] did.
- GC1-5 is a human-derived malignant stem cell derived from primary cultured (non-embryonic) cells prepared from fresh cancer tissue (stomach cancer tissue) of cancer patients.
- Endogenous stromal barrier-related genes (COL4A2 gene, FN1 The gene, COL1A1 gene, and TGFB1 gene) were found to be relatively highly expressed.
- GC1-5 is a human-derived malignant stem cell derived from a primary culture (non-embryonic) cell prepared from a fresh cancer tissue (gastric cancer tissue) of a cancer patient, and an endogenous epithelial-mesenchymal transition associated gene (VIM gene) COL3A1 gene and COL1A2 gene) were found to be relatively highly expressed.
- VIP gene epithelial-mesenchymal transition associated gene
- human induced endoderm malignant stem cell NGC1-1 human embryonic stem cell hES_H9 (GSM194390) and human induced pluripotent stem cell hiPS-201B7 of the present invention
- human induced endoderm malignant stem cell CC1- Table 39 hES_H9 vs NGC1-1
- Table 40 hiPS-201B7 vs NGC1-1
- Table 41 hiPS-201B7 vs CC1-10
- CC1-1 is a human-derived malignant stem cell derived from a primary culture (non-embryonic) cell prepared from a fresh cancer tissue (colon cancer tissue) of a cancer patient, and a self-replication-related gene (POU5F1 gene, It was revealed that NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene) were expressed.
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9 (GSM194390 Table 42 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression has been increased two-fold or more in comparison with (1).
- NGC1-1 is a human-derived malignant stem cell derived from a primary culture (non-embryonic) cell prepared from fresh non-cancerous tissue (non-cancerous tissue of the stomach) of cancer patients, and endogenous gastric cancer-related gene (CCND2 The gene, TIMP3 gene, LOX gene, and RASSF1 gene) were found to be relatively highly expressed.
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9.
- Table 43 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than doubled compared to (GSM194390).
- NGC1-1 is a human-derived malignant stem cell derived from a primary culture (non-embryonic) cell prepared from fresh non-cancerous tissue (non-cancerous tissue of the stomach) of a cancer patient. It was revealed that the IGF2 gene, INHBA gene, MDK gene, INHBB gene, and BMP1 gene) were relatively highly expressed.
- TGF ⁇ / BMP signal related genes Among the probes of TGF ⁇ / BMP signal related genes mounted on Agilent Whole Human Genome Oligo DNA Microarray (4X44K), the human induced endoderm malignant stem cell GC1-5 of the present invention is human.
- Table 44 [hES_ES01 vs GC1] shows the gene symbol, GenBank accession number, and probe of the gene whose expression is more than twice as high as that of embryonic stem cell hES_ES01 (GSM194392) and human induced pluripotent stem cell hiPS-201B7. -5] and Table 45 [hiPS-201B7 vs GC1-5].
- GC1-5 is a human-derived malignant stem cell derived from a primary culture (non-embryonic) cell prepared from a fresh cancer tissue (gastric cancer tissue) of a cancer patient.
- An endogenous TGF ⁇ / BMP signal-related gene (TGFB1 gene, It was revealed that IGFBP3 gene, INHBA gene, and INHBB gene) were relatively highly expressed.
- human induced endoderm malignant stem cell NGC1-1 of the present invention human embryonic stem cell hES_ES01 (GSM194392) and human induced pluripotent stem cell hiPS-201B7, human induced endoderm malignant stem cell CC1-10 of the present invention and The results of comparison between human embryonic stem cells hES_ES01 (GSM194392) and human induced pluripotent stem cells hiPS-201B7 are shown in Table 46 [hES_ES01 vs NGC1-1], Table 47 [hiPS-201B7 vs NGC1-1], Table 48 [ hES_ES01 vs CC1-10] and Table 49 [hiPS-201B7 vs CC1-10].
- NGC1-1 is a human-derived malignant stem cell derived from primary cultured (non-embryonic) cells prepared from fresh non-cancerous tissue (stomach non-cancerous tissue) of cancer patients and is associated with endogenous TGF ⁇ / BMP signaling It was revealed that the gene (TGFB1 gene, IGFBP3 gene, INHBA gene, INHBB gene) was expressed.
- CC1-10 is a human-derived malignant stem cell derived from a primary culture (non-embryonic) cell prepared from a fresh cancer tissue (colon cancer tissue) of a cancer patient, and is an endogenous TGF ⁇ / BMP signal-related gene. It was revealed that (TGFB1 gene, IGFBP3 gene, INHBA gene, INHBB gene) were relatively highly expressed.
- GC1-5 Tissue invasion / metastasis-related genes Among the probes of tissue invasion / metastasis-related genes mounted on Agilent Whole Human Genome Oligo DNA Microarray (4X44K), the human induced endoderm malignant stem cell GC1-5 of the present invention
- Table 50 [hiPS-201B7 vs GC1-5] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than 2-fold increased compared to human induced pluripotent stem cells hiPS-201B7 .
- GC1-5 is a human-derived malignant stem cell derived from primary cultured (non-embryonic) cells prepared from fresh cancer tissue (stomach cancer tissue) of cancer patients.
- Endogenous tissue invasion / metastasis-related gene FST gene
- the BMP7 gene, TGFB1 gene, and COL3A1 gene) were found to be relatively highly expressed.
- Table 51 [hiPS-201B7 vs NGC1-1] shows the results of comparing the human induced endoderm malignant stem cell NGC1-1 of the present invention with the human induced pluripotent stem cell hiPS-201B7. Furthermore, the figure which plotted the probe of the tissue invasion / metastasis-related gene whose expression is increased more than 2 times is shown (FIG. 4).
- Human-derived malignant stem cells are derived from primary cultured (non-embryonic) cells prepared from fresh non-cancerous tissues (non-cancerous tissues of the stomach) of cancer patients, and endogenous tissue invasion / metastasis-related genes (FST)
- the gene, BMP7 gene, TGFB1 gene, and COL3A1 gene) were found to be relatively highly expressed.
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9.
- Table 52 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased more than 2-fold compared to (GSM194390). Furthermore, the figure which plotted the probe of the Wnt signal related gene whose expression has risen 2 times or more is shown (FIG. 5).
- the induced malignant stem cells were found to express relatively high endogenous Wnt signal-related genes (CCND2 gene, SLC9A3R1 gene, LEF1 gene, CTNNB1 gene, FRZB gene).
- the human induced endoderm malignant stem cell GC1-5 of the present invention is human embryonic stem cell hES_H9.
- Table 53 [hES_H9 vs GC1-5] below shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased two or more times compared to (GSM194390).
- Induced malignant stem cells have been found to express relatively high levels of endogenous signaling-related genes (CCL2 gene, CDKN1A gene, HSPB1 gene, RBP1 gene, CCND1 gene, LEF1 gene, GADD45A gene, BAX gene). It was.
- Notch signal-related gene Among the probes of Notch signal-related gene mounted on Agilent Whole Human Genome Oligo DNA Microarray (4X44K), the human induced endoderm malignant stem cell GC1-5 of the present invention is human embryonic stem cell hES_H9.
- Table 54 [hES_H9 vs GC1-5] below shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased two or more times compared to (GSM194390). Induced malignant stem cells were found to express relatively high levels of endogenous Notch signal-related genes (CD44 gene, FZD2 gene, CCND1 gene, HES1 gene, CDKN1A gene).
- the human induced endoderm malignant stem cell GC1-5 of the present invention is human embryonic.
- the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than twice as high as that of stem cells hES_H9 (GSM194390) are shown in Table 56 below [hES_H9 vs GC1-5].
- the induced malignant stem cells were found to express relatively high endogenous colon cancer-related genes (DKK3 gene, SPARC gene, IGF2 gene).
- hypoxia signal-related genes Among the probes of hypoxia signal-related genes mounted on Agilent's Whole Human Genome oligo DNA microarray (4X44K), the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic.
- Table 57 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased two or more times compared to stem cells hES_H9 (GSM194390). Induced malignant stem cells were found to express relatively high endogenous hypoxia signal-related genes (EPAS1, TUBA4, EEF1A1, and CDC42 genes).
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9.
- Table 58 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than doubled compared to (GSM194390). It was revealed that the induced malignant stem cells expressed relatively high endogenous GPCR signal-related genes (GNAS gene, RGS2 gene, JUNB gene, AGT gene).
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9.
- Table 59 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased by 2 times or more compared to (GSM194390).
- the induced malignant stem cells were found to express relatively high endogenous drug resistance-related genes (AQP1 gene, SLC16A3 gene, ATP6V0C gene, MVP gene, ABCG2 gene, ATP7B gene).
- Hedgehog signal-related gene Among Hedgehog signal-related gene probes mounted on Agilent Whole Human Genome Oligo DNA Microarray (4X44K), the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9.
- Table 60 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than doubled compared to (GSM194390).
- the induced malignant stem cells were found to be relatively highly expressing endogenous Hedgehog signal-related genes (CTNNB1, FGFR3, and ERBB4).
- PI3K-AKT signal-related gene Among the probes of the PI3K-AKT signal-related gene mounted on Agilent Whole Human Genome Oligo DNA Microarray (4X44K), the human induced endoderm malignant stem cell NGC1-1 of the present invention is human.
- Table 61 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased more than 2-fold compared to embryonic stem cells hES_H9 (GSM194390). It was revealed that the induced malignant stem cells expressed relatively high endogenous PI3K-AKT signal-related genes (HSPB1, ITGB1, CTNNB1, PDGFRA, and FKBP1A genes).
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9 (GSM194390 Table 62 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased 2 times or more compared to The induced malignant stem cells were found to express relatively high endogenous drug metabolism genes (PKM2 gene, GSTM3 gene, COMT gene, ALDH1A1 gene, BLVRB gene).
- human induced endoderm malignant stem cell NGC1-1 of the present invention is Table 63 [hiPS-201B7 vs NGC1-1] below shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased two or more times compared to the ability stem cells hiPS-201B7. Induced malignant stem cells were found to be relatively highly expressed in endogenous molecular mechanism genes (BAX gene, NFKBIA gene, BCL2 gene, CASP8 gene).
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic.
- Table 64 [hES_ES01 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than twice as high as that of stem cells hES_ES01 (GSM194392).
- the induced malignant stem cells were found to be relatively highly expressed in endogenous SMAD signal network-related genes (PSMC3 gene, HDAC5 gene, UBB gene, ACTA2 gene).
- pancreatic cancer-related genes Among the probes of pancreatic cancer-related genes mounted on Agilent's Whole Human Genome oligo DNA microarray (4X44K), the human induced endoderm malignant stem cell NGC1-1 of the present invention is highly human-induced.
- Table 65 [hiPS-201B7 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased by 2 times or more compared with the ability stem cell hiPS-201B7. Induced malignant stem cells were found to be relatively highly expressing endogenous pancreatic cancer-related genes.
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is Table 66 [hES_BG03 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of the genes whose expression is increased more than 2-fold compared to human embryonic stem cells hES_BG03 (GSM194391).
- the induced malignant stem cells were found to be relatively highly expressed in endogenous prostate cancer-related genes (SFRP1, TIMP2, DKK3, and DLC1 genes).
- liver cancer-related genes Among the probes of liver cancer-related genes mounted on Agilent's Whole Human Genome oligo DNA microarray (4X44K), the human induced endoderm malignant stem cell GC1-5 of the present invention is human embryonic.
- Table 67 [hES_BG03 vs GC1-5] below shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than twice as high as that of stem cells hES_BG03 (GSM194391).
- the induced malignant stem cells were found to express relatively high levels of endogenous liver cancer-related genes (CCND2, DLC1, CDKN1A, and DAB2IP genes).
- the human induced endoderm malignant stem cells GC1-5 of the present invention are human embryonic stem cells hES_BG03 (GSM194391 Table 68 [hES_BG03 vs GC1-5] below shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased more than twice as compared to (1).
- the induced malignant stem cells were found to be relatively highly expressed in endogenous lung cancer-related genes (CDKN1C gene, MGMT gene, RASSF2 gene, CADM1 gene).
- the human induced endoderm malignant stem cell GC1-5 of the present invention is human embryonic.
- the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than twice as high as those of stem cell hES_H9 (GSM194390) are shown in Table 69 below [hES_H9 vs GC1-5].
- the induced malignant stem cells were found to express relatively high endogenous stress and toxicity-related genes (GDF15 gene, GSTM3 gene, HMOX1 gene, HSPA5 gene).
- the human induced endoderm malignant stem cell NGC1-1 of the present invention is human embryonic stem cell hES_H9.
- Table 71 [hES_H9 vs NGC1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than doubled compared to (GSM194390). Induced malignant stem cells were found to have relatively high expression of stem cell transcription factor genes (NR2F2 gene, PITX2 gene, HAND1 gene, ZIC1 gene).
- the human induced endoderm malignant stem cell GC1-5 of the present invention is human embryonic stem cell hES_BG03.
- Table 72 [hES_BG03 vs. GC1-5] below shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased two or more times compared to (GSM194391).
- Induced malignant stem cells have relatively high expression of hepatocyte-related genes (TTR gene, DLK1 gene, AFP gene, TF gene) in addition to any of 1) to 31) compared to human embryonic stem cell hES_H9 (GSM194390) It became clear that it was rising.
- the human induced endoderm malignant stem cell GC1-5 of the present invention is the human embryonic stem cell hES_H9.
- Table 73 [hES_H9 GC1-5] below shows the gene symbols, GenBank accession numbers, and probes of the genes that are expressed to the same extent (1/2 to 2 times) compared to (GSM194390).
- a probe of a self-replication-related gene expressed approximately the same level (1/2 to 2 times) of human induced endoderm malignant stem cell NGC1-1 of the present invention and human embryonic stem cell hES_BG03 (GSM194391) A graph in which is plotted (FIG. 6).
- all of the self-replication related genes in Table 1 are almost the same level (1/8 to 8 times) compared with human induced endoderm malignant stem cell GC1-5 of the present invention and human embryonic stem cell hES_H9 (GSM194390). It was expressed.
- human induced endoderm malignant stem cell NGC1-1 and human embryonic stem cell hES_BG03 GSM194391
- human induced endoderm malignant stem cell CC1-10 and human embryonic stem cell hES_BG03 GSM194391
- all of the self-replication related genes in Table 1 are compared with the human induced endoderm malignant stem cell NGC1-1, human induced endoderm malignant stem cell CC1-10, human embryonic stem cell hES_H9 (GSM194390) of the present invention.
- induced malignant stem cells express self-replication-related genes (POU5F1, NANOG, SOX2, ZFP42, LIN28, TERT) in addition to any one of genes 1) to 31).
- POU5F1, NANOG, SOX2, ZFP42, LIN28, TERT self-replication-related genes
- FIG. 8 shows a plot of the self-replication-related gene probe (FIG. 8).
- induced malignant stem cells express self-replication-related genes (POU5F1, NANOG, SOX2, ZFP42, LIN28, TERT) in addition to any one of genes 1) to 31).
- self-replication-related genes POU5F1, NANOG, SOX2, ZFP42, LIN28, TERT
- Induced malignant stem cells express self-replication-related genes (POU5F1, NANOG, SOX2, ZFP42, LIN28, and TERT genes) in addition to any one of genes 1) to 31).
- human-induced malignant stem cells not only have an increased expression of malignant marker genes (cancer-related genes), which are cancerous properties, compared to human embryonic stem cells, but also embryonic stem cells. It has been experimentally verified that the self-replication-related genes (POU5F1, NANOG, SOX2, ZFP42, LIN28, and TERT genes) that are characteristic of the gene are expressed to the same extent as human embryonic stem cells.
- Example 6 Examination of karyotype of human induced malignant stem cells by band staining method and mode analysis About induced malignant stem cells (NGC1-1) of Example 3, 20 cells / strain by G band staining method, 50 by mode analysis Cells / strains were examined for karyotype and number of chromosomes. As a result, all of these induced malignant stem cells were 46XY karyotype and normal. Induced malignant stem cells (NGC1-1: 76 days after gene introduction) were analyzed for cells cultured on MEF using mTeSR1 or the like. The induced malignant stem cells were normal karyotype cells.
- Example 7 Chromosome Examination of Human-Induced Malignant Stem Cells by Multicolor FISH
- the induced malignant stem cells (NGC1-1) of Example 3 were examined for chromosome deletion and translocation of 10 cells / strain by multicolor FISH. As a result, all of these induced malignant stem cells had normal chromosomes (no abnormality was detected).
- Induced malignant stem cells (NGC1-1: 76 days after gene introduction) were analyzed for cells cultured on MEF using mTeSR1. Induced malignant stem cells were cells without chromosomal abnormalities (chromosomal translocations and deletions).
- Example 8 Tumor marker- induced malignant stem cell (NGC1-1) culture supernatant in human-derived malignant stem cell culture supernatant was analyzed by clinical laboratory company SRL. As a result, the induced malignant stem cells were TGF ⁇ 1, AFP, and procollagen III. Peptides (P-III-P), type IV collagen, apolipoprotein C-II, prealbumin (TTR), and IGF-I protein were found to be produced. From this result, it was found that induced malignant stem cells are cells that produce tumor markers.
- Example 9 Tumor formation in experimental animals of human induced malignant stem cells (production of a tumor bearing model)
- the induced malignant stem cells (NGC1-1) of Example 3 were transplanted into mice, and the following experiments were conducted for observation of tissue images of cancer cells derived from malignant cells and preparation of a tumor bearing model.
- Mouse-derived malignant stem cells were transplanted subcutaneously into the back of the mice together with NOD / SCID mice, which are immunodeficient animals, at 5 ⁇ 10 6 cells / 100 ⁇ l per mouse together with 200 ⁇ l matrigel. In addition, 5 ⁇ 10 6 cells / 500 ⁇ l were transplanted into the mouse abdominal cavity. As a result, tumors were formed in tumor-bearing mice transplanted with induced malignant stem cells (NGC1-1) after 2 to 3 months.
- tumors formed from induced malignant stem cells are tissues that have undergone epithelial-mesenchymal transition and have formed a stromal barrier. there were. Therefore, it was found that some induced malignant stem cells (NGC1-1) form a stromal barrier.
- the malignant tumor tissue was fixed in formalin, a paraffin section was prepared, stained with hematoxin and eosin, and observed under a microscope. Cancer tissues that formed an interstitial barrier rich in extracellular matrix and stromal cells were observed together with intestinal tract-like tissues. Therefore, it was confirmed that the transplanted cells are human induced malignant stem cells that undergo epithelial-mesenchymal transition.
- Example 10 Single sort of human induced malignant stem cells 1 cell / well (unstained)
- the induced malignant stem cells (GC1-2, NGC1-1) of Example 3 were single-sorted into 96-well plates at 1 cell / well using PERFLOW TM Sort manufactured by Furukawa Electric.
- PERFLOW TM Sort manufactured by Furukawa Electric.
- monoclonal induced malignant stem cells GC1-2-1, GC1-2-2, GC1-2-3, GC1-2-4, NGC1-1-1, NGC1-1-2, NGC1-1-3 NGC1-1-4
- Example 11 Single sort of human induced malignant stem cells 1 cell / well (staining with specific antibody) CD34 (Alexa fluor 488-conjugated mouse monoclonal antibody anti-human CD34; manufactured by Biolegend; clone: 581; mouseIgG1)), VEGFR2 (Alexa fluor 647-conjugated mouse monoclonal antibody anti-human CD309; manufactured by Biolegend; clone: HKDR- 1; mouseIgG1)), PDGFR ⁇ (PE-conjugated anti-human CD140a; manufactured by Biolegend; clone: 16A1; mouseIgG1), DLK-1 (mouse monoclonal antibody anti-human Pref-1 / DLK-1 / FA1; manufactured by R & D) Clone #: MAB1144; mouseIgG2B), CXCR4 (Carboxyfluorescein (CFS) -conjugated mouse monoclonal antibody anti-human CXCR4; manufactured by R &
- Example 12 Preparation of Retroviral Vector for Gene Transfer into Cancer Tissue-Derived Cells of Familial Tumor Patient
- a retroviral vector solution was prepared so that POU5F1> SOX2. Details are as follows ⁇ Preparation of retroviral vector solution for gene transfer into cells derived from skin tissue of patients with familial colon polyposis (APC)> Genes POU5F1-pMXs, KLF4-pMXs, and SOX2-pMXs are constructed vectors (Table 33 above).
- the amount of each vector is POU5F1-pMXs MX5 ⁇ g, KLF4-pMXs 2.5 ⁇ g, SOX2-pMXs 1.25 ⁇ g, Venus-pCS2 1.25 ⁇ g, VSV-G-pCMV 5 ⁇ g, GFP-pMXs (Cell Biolab) 1.25 ⁇ g, FuGENE HD 45 ⁇ l It was.
- the amount of each vector is POU5F1-pMXs MX5 ⁇ g, KLF4-pMXs 2.5 ⁇ g, SOX2-pMXs 1.25 ⁇ g, Venus-pCS2 1.25 ⁇ g, VSV-G-pCMV 5 ⁇ g, GFP-pMXs (Cell Biolab) 1.25 ⁇ g, FuGENE HD 45 ⁇ l It was.
- the amount of each vector is POU5F1-pMXs MX5 ⁇ g, KLF4-pMXs 2.5 ⁇ g, SOX2-pMXs 1.25 ⁇ g, Venus-pCS2 1.25 ⁇ g, VSV-G-pCMV 5 ⁇ g, GFP-pMXs (Cell Biolab) 1.25 ⁇ g, FuGENE HD 45 ⁇ l It was.
- POU5F1-KLF4-SOX2-pMXs 8.4 kb is excised from the EcoRI-EcoRI insert part (3700 bp) of pCX-OKS-2A (8478 bp) and recombined with the EcoRI-EcoRI part (1122 bp) of pMXs (5871 bp) This is a constructed vector. Furthermore, it was confirmed to be forward from the 5 ′ end to the 3 ′ end. (Table 76 below).
- the amount of each vector was POU5F1-KLF4-SOX2-pMXs 3 ⁇ g, Venus-pCS2 0.5 ⁇ g, VSV-G-pCMV 2 ⁇ g, FuGENE HD 15 ⁇ l.
- the use of POU5F1-KLF4-SOX2-pMXs means that POU5F1, KLF4, and SOX2 genes were used in a 1: 1: 1 ratio in this order.
- the 1: 1: 1 ratio may be used when a gene is introduced into a packaging cell.
- a retroviral vector solution of 3 genes of POU5F1-pMXs, KLF4-pMXs and SOX2-pMXs can be prepared separately. You may mix by the ratio of 1: 1.
- Example 13 Production of human-derived precancerous stem cells from cells derived from APC patient skin tissue APC patient (APC3223, 25 years old, male, white, 541st glutamine [541 Gln, Q: CAA or CAG]
- Human-derived endoderm-derived precancerous stem cells having a mutation of APC, an endogenous tumor suppressor gene, from somatic cells of the skin tissue (frozen passage number: 2) replaced with T base to become a stop codon Established as follows.
- One vial of cells derived from skin tissue of a cryopreserved familial adenomatous patient was thawed in a 37 ° C.
- D-MEM high glucose medium containing 10% of antibiotic-antifungal agent and FBS to obtain 10 ml of cell suspension.
- Cells derived from skin tissue of patients with familial adenomatous adenomatosis (APC) are precancerous cells that have a germline (genetic) allelic APC mutation (541 Gln ⁇ ter: C ⁇ T).
- the obtained cell suspension was centrifuged at 1000 rpm and 4 ° C. for 5 minutes, and the supernatant was removed. Then, D-MEM (high glucose) containing 10% of 1 ⁇ antibiotic-antifungal agent and FBS was used. ) Suspended in 20 ml of medium to obtain a cell suspension. The resulting cell suspension is 10 ml / dish on a 90 mm diameter cell culture Petri dish (Nunk; Cat no. 172958) coated with Matrigel at a concentration of 20 ⁇ g / cm 2 for at least 30 minutes on the bottom. Cells were seeded by adding.
- the medium was removed, and 10 ml of 3 genes (POU5F1, KLF4, SOX2 ratio in order 4: 2: 1) retroviral vector solution was added and infected at 37 ° C. for 24 hours.
- the virus supernatant was removed, 10 ⁇ l of MEF-conditioned ES medium was added, and cultured at 37 ° C. for one day. Thereafter, the MEF-conditioned ES medium was continuously changed every two days.
- the medium was changed daily with the mTeSR1 medium for human ES / iPS cells for free of feeder cells.
- the medium was changed daily with MEF-conditioned ES medium from 28 days to 32 days after gene transfer. From day 33 after gene transfer, the medium was replaced with a new medium for human ES / iPS cells mTeSR1 for free of feeder cells every day.
- the feeder cells were mouse embryonic fibroblasts (DS Pharma Biomedical; Cat no.
- R-PMEF-CF that had been treated with mitomycin, and 5.0 ⁇ 10 4 cells / day before picking up induced malignant stem cells. It was seeded in gelatin-coated 24-well plates (Cat no.11-020-012 manufactured by Iwaki) at cm 2.
- APC (3223) 1-3 Number of days after gene transfer 59: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) 75 days after gene transfer: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) 79 days after gene transfer: Preservation.
- APC (3223) 1-4 Number of days after gene transfer 59: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) 75 days after gene transfer: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) 79 days after gene transfer: Preservation.
- human-induced precancerous stem cells having mutations in endogenous tumor suppressor genes were prepared. These clones were human induced endoderm precancerous stem cells with germline mutations on one side allele of the endogenous tumor suppressor gene (APC).
- APC endogenous tumor suppressor gene
- Example 14 Production of human-derived precancerous stem cells from cells derived from APC patient skin tissue APC patient (APC3946, 22 years old, female, Caucasian, 541th glutamine [541 Gln, Q: CAA or CAG] Substitution with T base to become a stop codon. Siblings with APC3223 mentioned above. From human skin tissue (frozen passage number: 2), human induced endoderm precancerous stem cells were established as follows: did. One cryogenic vial of cells derived from skin tissue of a patient with familial adenomatous adenomatosis (CORIELL; Cat no. GM03946) was thawed in a 37 ° C constant temperature bath, and 1x antibiotic-antifungal and FBS was suspended in D-MEM (high glucose) medium containing 10% to obtain 10 ml of cell suspension.
- D-MEM high glucose
- the obtained cell suspension was centrifuged at 1000 rpm and 4 ° C. for 5 minutes, and the supernatant was removed. Then, D-MEM (high glucose) containing 10% of 1 ⁇ antibiotic-antifungal agent and FBS was used. ) Suspended in 20 ml of medium to obtain a cell suspension. Cells were seeded by adding 10 ml / dish of the obtained cell suspension onto a 90 mm cell culture Petri dish coated with Matrigel at a concentration of 20 ⁇ g / cm 2 for 30 minutes or more on the bottom surface.
- the medium was removed, and 10 ml of 3 genes (POU5F1, KLF4, SOX2 ratio in order 4: 2: 1) retroviral vector solution was added and infected at 37 ° C. for 24 hours.
- the virus supernatant was removed, 10 ⁇ l of MEF-conditioned ES medium was added, and cultured at 37 ° C. for one day. Thereafter, the MEF-conditioned ES medium was continuously changed every two days.
- the medium was changed daily with the mTeSR1 medium for human ES / iPS cells for free of feeder cells.
- the medium was changed daily with MEF-conditioned ES medium from 28 days to 32 days after gene transfer.
- the medium was changed daily with the feeder cell free human ES / iPS cell medium mTeSR1.
- colonies were picked up with 1 clone (1-1) and 40 days later with 1 clone (1-2) tweezers, transferred onto feeder cells, and cultured with mTeSR1.
- the feeder cells were mouse embryonic fibroblasts (DS Pharma Biomedical; Cat no.
- R-PMEF-CF that had been treated with mitomycin, and 5.0 ⁇ 10 4 cells / day before picking up induced malignant stem cells. It was seeded in gelatin-coated 24-well plates (Cat no.11-020-012 manufactured by Iwaki) at cm 2.
- human-induced precancerous stem cells having mutations in endogenous tumor suppressor genes were prepared. These clones were human induced endoderm precancerous stem cells with germline mutations on one side allele of the endogenous tumor suppressor gene (APC).
- APC endogenous tumor suppressor gene
- APC Human-derived endoderm-derived precancerous stem cells derived from skin tissue of APC patients> APC (3946) 1-1 Days after gene transfer 54: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 61: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) 72 days after gene transfer: Passage (4th passage) and storage 77 days after gene transfer: Buffer RLT (cell lysate before RNA purification) treatment and storage (5th pass).
- APC 1-1 Days after gene transfer 54: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 61: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) 72 days after gene transfer: Passage (4th passage) and storage 77 days after gene transfer: Buffer RLT (cell lysate before RNA purification) treatment and storage (5th pass).
- APC (3946) 1-2 Number of days after gene transfer 59: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 61: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) 72 days after gene transfer: Passage (4th passage) and storage 77 days after gene transfer: Buffer RLT (cell lysate before RNA purification) treatment and storage (5th pass).
- human-induced precancerous stem cells having mutations in endogenous tumor suppressor genes were prepared. These clones were human induced endoderm precancerous stem cells with germline mutations on one side allele of the endogenous tumor suppressor gene (APC).
- APC endogenous tumor suppressor gene
- Example 15 Preparation of human-derived precancerous stem cells from RB patient skin tissue-derived cells RB patient (1-year-old male, Japanese, RB1 codon [706: TGT] G base replaced with A base Human-derived precancerous stem cells having a mutation in the endogenous tumor suppressor gene were established from the skin tissue (passage number 3) as follows.
- the obtained cell suspension was centrifuged at 1000 rpm and 4 ° C. for 5 minutes, the supernatant was removed, and then suspended in 20 ml of FGM-2 BulletKit to obtain a cell suspension.
- Cells were seeded by adding 10 ml / dish of the obtained cell suspension onto a 90 mm cell culture Petri dish coated with Matrigel at a concentration of 20 ⁇ g / cm 2 for 30 minutes or more on the bottom surface.
- the medium was removed, 10 ml of 3 gene retrovirus vector solution was added, and the cells were infected at 37 ° C. for 24 hours.
- the virus supernatant was removed, 10 ⁇ l of MEF-conditioned ES medium was added, and cultured at 37 ° C. for one day. Thereafter, the MEF-conditioned ES medium was continuously changed every two days.
- the medium was changed daily with mTeSR1, a medium for human ES / iPS cells for free of feeder cells. 26 days after gene transfer 4 colonies (1-4, 1-7, 1-8, 1-9), 33 days later with 3 clones (1-2, 1-5, 1-6) tweezers Picked up and transferred onto feeder cells.
- the feeder cells were mouse embryonic fibroblasts (DS Pharma Biomedical; Cat no. R-PMEF-CF) that had been treated with mitomycin, and 5.0 ⁇ 10 4 cells / day before picking up induced malignant stem cells. It was seeded in gelatin-coated 24-well plates (Cat no.11-020-012 manufactured by Iwaki) at cm 2.
- RB Human-derived precancerous stem cells derived from skin tissue of RB patients> RB (203) 1-2 Days after gene transfer 49: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 77: 6-well plate (second passage) ⁇ 10 cm culture dish (passage 3) 82 days after gene transfer: Preservation.
- RB203 (1-5) Days after gene transfer 53: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 60: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) Number of days after gene transfer 66: Passage (passage 4) and storage Days after gene transfer 69: Buffer RLT (cell lysate before RNA purification) treatment and storage.
- RB203 (1-6) Days after gene transfer 53: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 59: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) Days after gene transfer 63: Passage (4th passage) and storage Days after gene transfer 66: Buffer RLT (cell lysate before RNA purification) treatment and storage.
- human-induced precancerous stem cells having mutations in endogenous tumor suppressor genes were prepared. These clones were human-induced precancerous stem cells with germline mutations on one side allele of the endogenous tumor suppressor gene (RB1).
- Example 16 Production of human-derived malignant stem cells from cells derived from cancer tissue of RB patients RB patients (1-year-old male, Japanese, 706 codon of RB1 gene (706: TGT) G who are familial tumor patients A human-derived malignant stem cell having a mutation in an endogenous tumor suppressor gene was established from a cancer tissue (retinoblastoma) in which the base was replaced with an A base as follows.
- cryopreserved retinoblastoma vial of cryopreserved retinoblastoma (National Institute for Pharmaceutical Sciences; resource number: KURB2359 lot number: 091285) in a 37 ° C constant temperature bath, 1x antibiotics-
- the suspension was suspended in a D-MEM (high glucose) medium containing 10% of an antifungal agent and FBS to obtain 10 ml of a cell suspension.
- D-MEM high glucose
- the obtained cell suspension was centrifuged at 1000 ° C. and 4 ° C. for 5 minutes, and the supernatant was removed. Then, D-MEM (high glucose) containing 10% of 1 ⁇ antibiotic-antifungal agent and FBS was used. ) 40 ⁇ l of medium was added and centrifuged again at 1000 ⁇ rpm and 4 ° C. for 5 minutes. Next, after removing the supernatant, 20 ⁇ l of D-MEM (high glucose) medium containing 10% of 1 ⁇ antibiotic-antimycotic agent and FBS was added, and collagen coated dish 100 mm (made by Iwaki, Cat ⁇ no.11) -018-006).
- the MEF-conditioned ES medium was continuously changed every 3 days, and the medium was changed daily with the feeder cell-free human ES / iPS cell medium mTeSR1 21 days after the gene transfer.
- mTeSR1 a medium for human ES / iPS cells for free of feeder cells.
- Twenty-one days after gene transfer colonies were picked up with 5 clones (1-1, 1-2, 1-3, 1-4, 1-6) tweezers and transferred onto feeder cells.
- the feeder cells were mouse embryonic fibroblasts (DS Pharma Biomedical; Cat no. R-PMEF-CF) that had been treated with mitomycin, and 5.0 ⁇ 10 4 cells / day before picking up induced malignant stem cells. It was seeded in gelatin-coated 24-well plates (Cat no.11-020-012 manufactured by Iwaki) at cm 2.
- RBT203 (1-2) Days after gene transfer 32: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) 56 days after gene transfer: 6-well plate (second passage) ⁇ 10 cm culture dish (passage 3) 61 days after gene transfer: Preservation.
- RBT203 (1-3) Days after gene transfer 32: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) 56 days after gene transfer: 6-well plate (second passage) ⁇ 10 cm culture dish (passage 3) 61 days after gene transfer: Preservation.
- RBT203 (1-4) Number of days after gene transfer 32: Well plate (1st passage) ⁇ Well plate (2nd passage) Days after gene transfer 39: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) Days after gene transfer 45: Passage and storage Days 48 after gene transfer: Buffer RLT (cell lysate before RNA purification) treatment and storage.
- RBT203 (1-6) Days after gene transfer 32: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 39: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) Days after gene transfer 45: Passage and storage Days 48 after gene transfer: Buffer RLT (cell lysate before RNA purification) treatment and storage.
- human induced malignant stem cells having a mutation in the endogenous tumor suppressor gene were prepared. These clones were human-induced malignant stem cells with germline mutations on one side allele of the endogenous tumor suppressor gene (RB1).
- Example 17 Production of human induced precancer stem cells from RB patient skin tissue-derived cells From human skin tissue (passage number 1) of RB patients (2 years old, female, Japanese) Established as follows.
- One somatic cell derived from the skin tissue of a patient with cryopreserved retinoblastoma (National Institute for Pharmaceutical Sciences; resource number: KURB2435 lot number: 080687) is thawed in a 37 ° C constant temperature bath and 1x antibiotic-anti It was suspended in a D-MEM (high glucose) medium containing 10% of a fungal agent and FBS to obtain 20 ml of a cell suspension.
- D-MEM high glucose
- the obtained cell suspension was centrifuged at 1000 rpm and 4 ° C. for 5 minutes, the supernatant was removed, and then suspended in 20 ml of FGM-2 BulletKit to obtain a cell suspension.
- Cells were seeded by adding 10 ml / dish of the obtained cell suspension onto a 90 mm cell culture Petri dish coated with Matrigel at a concentration of 20 ⁇ g / cm 2 for 30 minutes or more on the bottom surface.
- the medium was removed, 10 ml of 3 gene retrovirus vector solution was added, and the cells were infected at 37 ° C. for 24 hours.
- the virus supernatant was removed, 10 ⁇ l of MEF-conditioned ES medium was added, and cultured at 37 ° C. for one day. Thereafter, the MEF-conditioned ES medium was continuously changed every two days.
- the medium was changed with mTeSR1, a medium for human ES / iPS cells for free of feeder cells. After 18 days from gene transfer, the MEF-conditioned ES medium was continuously changed every 2 days. 36 days after the gene transfer, the medium was replaced with mTeSR1, a medium for human ES / iPS cells for feeder cell free. 38 days after the gene transfer, the MEF-conditioned ES medium was changed, and 51 days later, the medium was changed daily with the feeder cell free human ES / iPS cell medium mTeSR1. 53 days after gene transfer, colonies were picked up with 2 clones (1-1, 1-2) tweezers and transferred onto feeder cells.
- the feeder cells were mouse embryonic fibroblasts (DS Pharma Biomedical; Cat no. R-PMEF-CF) that had been treated with mitomycin, and 5.0 ⁇ 10 4 cells / day before picking up induced malignant stem cells. It was seeded in gelatin-coated 24-well plates (Cat no.11-020-012 manufactured by Iwaki) at cm 2.
- RB ⁇ Human-derived precancerous stem cells derived from skin tissue of RB patients> RB (243) 1-1 Days after gene transfer 61: 24-well plate (1st passage) ⁇ 6-well plate (2nd passage) Days after gene transfer 65: 6-well plate (2nd passage) ⁇ 10 cm culture dish (3rd passage) 74 days after gene transfer: Preservation.
- human-induced precancerous stem cells having mutations in endogenous tumor suppressor genes were prepared. These clones were human-induced precancerous stem cells with germline mutations on one side allele of the endogenous tumor suppressor gene (RB1).
- Example 18 Quantitative analysis by microarray of induced malignant stem cells derived from cancer tissues of patients with familial tumors Using human Whole Genome Oligo DNA microarray (4X44K) manufactured by Agilent, human induced malignant stem cells (RBT203 (1-1)) was analyzed. The analysis software was GeneSpring GX 10.0, and normalization was performed at 50th percentile. The experimental method is the same as in Example 5.
- the human induced malignant stem cell RBT203 (1-1) of the present invention is a human embryonic stem cell.
- Table 77 [hES_ES01 vs RBT203 (1-1)] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is more than twice as high as that of hES_ES01 (GSM194392). Furthermore, the figure which plotted the probe of the angiogenesis related gene in which expression rises 2 times or more is shown (FIG. 9). From the above, it was revealed that human-induced malignant stem cells are cells in which the expression of angiogenesis-related genes is increased more than twice.
- human-induced malignant stem cell RBT203 (1-1) is human-induced pluripotent stem cell hiPS
- Table 78 [hiPS-201B7 vs RBT203-1-1] shows the gene symbols, GenBank accession numbers, and probes of genes whose expression is increased two-fold or more compared to -201B7. Furthermore, the figure which plotted the probe of the signal transduction related gene whose expression rises 2 times or more is shown (FIG. 10). From the above, it has been clarified that human-induced malignant stem cells are cells in which the expression of signal transduction-related genes is increased more than twice.
- human-induced malignant stem cells express 6 genes (self-replication-related genes) of POU5F1 gene, NANOG gene, SOX2 gene, ZFP42 gene, LIN28 gene and TERT gene.
- human-derived malignant stem cells derived from cancer tissue of retinoblastoma (RB) patients who are familial tumor patients are characterized by not only increased expression of cancer-related genes but also embryonic stem cells. It was experimentally verified that a typical gene is expressed almost as well as human embryonic stem cells.
- the induced cancer stem cell of the present invention maintains (remains) abnormalities such as (a) mutation of a tumor suppressor gene, or (b) increased expression of a cancer-related gene, which the somatic cell has, and is infinite Can self-replicate. Therefore, since the induced cancer stem cells of the present invention can be subcultured for a long period of time and can be easily induced into cancer cells having the properties of tissue cells, the target screening method for cancer drug discovery, This method is very useful for research on cancer treatment and cancer-related drug discovery, such as screening methods and screening methods for cancer diagnostic agents, cancer vaccine production methods, and cancer model animal production.
Abstract
Description
(1)POU5F1遺伝子、NANOG遺伝子、SOX2遺伝子、ZFP42遺伝子、LIN28遺伝子及びTERT遺伝子の6遺伝子(自己複製関連遺伝子)を発現すること;そして
(2)(a)内在性のがん抑制遺伝子の変異、または(b)内在性のがん関連遺伝子の発現上昇のいずれかの異常を有すること;
を具備することを特徴とする、in vitroで増殖可能な誘導がん幹細胞を提供する。
本発明の第1の態様において、下記(1)および(2)の要件:
(1)POU5F1遺伝子、NANOG遺伝子、SOX2遺伝子、ZFP42遺伝子、LIN28遺伝子及びTERT遺伝子の6遺伝子(自己複製関連遺伝子)を発現すること;そして
(2)(a)内在性がん抑制遺伝子の変異、または(b)内在性がん関連遺伝子の発現上昇のいずれかの異常を有していること;
を具備することを特徴とする誘導がん幹細胞を提供する。この様な特徴を有する細胞は、in vitroで自己複製可能な誘導がん幹細胞であることが明らかになった。
本発明における前記(1)の遺伝子(自己複製関連遺伝子)は、胚性幹細胞のマーカー遺伝子として知られている遺伝子である。これらの遺伝子は、本発明の誘導がん幹細胞が、理論的には無限に自己複製し、事実上in vitroで自己複製可能な誘導がん幹細胞のまま長期継代培養可能な性質を有する細胞であることを特定する遺伝子(自己複製関連遺伝子)である。これらの遺伝子の具体的な例としては、以下の表1の遺伝子を挙げることができる。
本発明の誘導がん幹細胞は、(2)(a)内在性がん抑制遺伝子の変異、または(b)内在性がん関連遺伝子の発現上昇のいずれかの異常を有している。本発明の誘導がん幹細胞が有するこれらの異常は、誘導がん幹細胞の由来となる原料体細胞が本来有していた異常をそのまま承継するものである。
更に、本発明の誘導がん幹細胞においては、(b)前記内在性がん関連遺伝子に加え、ストレス及び毒性関連遺伝子群、エピジェネティクスクロマチン修飾酵素遺伝子群、幹細胞転写因子遺伝子群からなる群に含まれる遺伝子の群の中から選択される少なくとも1種の内在性の遺伝子に、遺伝子の発現上昇が生じていることが好ましい。
本発明の誘導がん幹細胞を増殖培養又は継代培養する培地としては、胚性幹細胞、多能性幹細胞等を増殖培養又は継代培養することが可能な培地であれば、特に制限されることはないが、胚性幹細胞、多能性幹細胞等の培養に適した培地が好ましく用いられる。このような培地としては、例えば、ES培地〔40%のダルベッコ改変イーグル培地(DMEM)、40%のF12培地(シグマ社製)、2 mM L-グルタミン又はGlutaMAX(シグマ社製)、1%の非必須アミノ酸(シグマ社製)、0.1 mMのβ-メルカプトエタノール(シグマ社製)、15~20%のノックアウト血清リプレースメント(インビトロジェン社製)、10μg/mlのゲンタマイシン(インビトロジェン社製)、4~10 ng/mlのFGF2因子〕、0.1 mMのβ-メルカプトエタノールを除いたES培地で、マウス胚性繊維芽細胞(以下MEF)を24時間培養した上清である馴化培地に、0.1 mMのβ-メルカプトエタノール及び10 ng/mlのFGF2を加えた培地(以下MEF馴化ES培地)、iPS細胞用最適培地(イプセロン社製)、フィーダー細胞用最適培地(イプセロン社製)、StemPro〔登録商標〕hESC SFM(インビトロジェン社製)、mTeSR1(ステムセルテクノロジー・ベリタス社製)、アニマルプロテインフリーのヒトES/iPS細胞維持用無血清培地TeSR2〔ST-05860〕(ステムセルテクノロジー・ベリタス社製)、霊長類ES/iPS細胞用培地(リプロセル社)、ReproStem(リプロセル社)、ReproFF(リプロセル社)、ReproFF2(リプロセル社)などを例示することができるが、これらの培地に制限されることはない。ヒトの細胞を用いる場合には、ヒト胚性幹細胞の培養に適した培地を用いてもよい。培養皿をコートする細胞外マトリックスとしては、ゼラチン、コラーゲン、マトリゲル、ラミニン、Synthemaxなどが用いられる。
本発明の第2の態様において、(a)がん抑制遺伝子の変異を有する哺乳動物から採取した体細胞、並びに、発がんした哺乳動物から採取した、(a)がん抑制遺伝子の変異、または(b)がん関連遺伝子の発現上昇のいずれかの異常を有する体細胞からなる群の中から選択された非胚性の原料体細胞から、in vitroで自己複製可能な誘導がん幹細胞を製造する、本発明の誘導がん幹細胞の製造方法を提供する。
本発明の誘導がん幹細胞は、本発明の誘導がん幹細胞の由来となる原料体細胞が本来有していた、(a)がん抑制遺伝子の変異、または(b)がん関連遺伝子の発現上昇等の異常をそのまま継承するため、原料となる体細胞、すなわち原料体細胞は、(a)がん抑制遺伝子の変異を有する哺乳動物から採取した体細胞、並びに、発がんした哺乳動物から採取した、(a)がん抑制遺伝子の変異、または(b)がん関連遺伝子の発現上昇のいずれかの異常を有する体細胞からなる群の中から選択された体細胞であることが必要である。
POU5F1遺伝子、KLF4遺伝子、及びSOX2遺伝子の各遺伝子シンボルに対するGenBankアクセッション番号は表31の通りである。
本発明の製造方法は、前記工程に加え、更に、1ウェルに1細胞をソーティングして増殖させる工程を含むことができる。この工程は、抗ALB抗体、抗FABP1抗体、抗IGF-II抗体、抗DLK1抗体、抗PDGFRα抗体、抗VEGFR2抗体、抗E-カドヘリン抗体、抗CXCR4抗体、抗PDGFRβ抗体、抗カドヘリン11抗体、抗CD34抗体、抗IGF-R1抗体から選択される何れか1つの抗体を使用した特異抗体染色を施した細胞、又は、未染色の細胞を、1ウェルに1細胞をソーティングする方法によって増殖させる工程である。
本発明の第3の態様において、本発明の誘導がん幹細胞を用いることを特徴とするスクリーニング方法であり、がん創薬標的のスクリーニング方法、がん治療薬のスクリーニング方法及びがん診断薬のスクリーニング方法として好適である。
本発明の第4の態様において、本発明の誘導がん幹細胞を用いた、がんワクチンの作製方法である。
本発明の第5の態様において、本発明の誘導がん幹細胞を用いた、がんモデル動物の作製方法である。
POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsの3遺伝子のレトロウイルスベクタープラスミドを、Fugene HD(ロシュ社製;Cat no.4709691)を用いて、パントロピックレトロウイルスベクター調製用パッケージング細胞であるPlat-GP細胞に導入し、レトロウイルスベクター液を調製した。遺伝子POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは順に4:2:1の比率で使用し、POU5F1>SOX2の関係になるようにした。詳細は、以下の通りである。
POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは構築したベクターである(後記表33)。
遺伝子POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは構築したベクターである(後記表33)。
遺伝子POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは構築したベクターである(後記表33)。
保存液に数時間保存・運搬したヒト胃がん(進行がん)患者の新鮮がん組織から体細胞を単離した。得られた胃がん患者がん組織由来の細胞に、実施例1において調製したPOU5F1>KLF4>SOX2の関係を満たす3遺伝子(POU5F1、KLF4、SOX2の比率が順に4:2:1)レトロウイルスベクター液を添加し、遺伝子導入することで、ヒト誘導悪性幹細胞を作製した。詳細は以下の通りである。
MEF
マイトマイシンC処理初代マウス胚性繊維芽細胞(DSファーマバイオメディカル社製;Cat no.R-PMEF-CF)
MEF馴化用ES培地
ノックアウトD-MEM(インビトロジェン社製;Cat no.10829-018)500 ml
2 mM GlutaMAX
10%ノックアウト血清リプレースメント(インビトロジェン社製;Cat no.10828-028)
50μg/mlゲンタマイシン(インビトロジェン社製;Cat no.15750-060)
MEM非必須アミノ酸液(インビトロジェン社製;Cat no.11140-050)
10 ng/ml bFGF(ぺプロテック社製;Cat no.100-18B)
<MEF馴化ES培地の調製>
マイトマイシン処理を行ったマウス胚性繊維芽細胞(DSファーマバイオメディカル社製;Cat no.R-PMEF-CF)5×106 cellを、1×抗生物質-抗真菌剤及びFBSを10%含むD-MEM(高グルコース)培地40 mlに懸濁後、ゼラチンコートディッシュ100 mm(イワキ社製;Cat no.11-020-006)4枚に播種した。24時間後に培地を除き、MEF馴化用のES培地を10 ml加えた。
3遺伝子導入から25日後に、誘導悪性幹細胞のコロニーを1クローン(GC1-1)、3遺伝子導入から32日後に、誘導悪性幹細胞のコロニーを1クローン(GC1-3)、3遺伝子導入から33日後に、誘導悪性幹細胞のコロニーを3クローン(GC1-5、7、8)ピックアップし、ゼラチンコート24ウェルプレート中のマイトマイシン処理を行ったフィーダー細胞上へ移した。なお、フィーダー細胞はマイトマイシン処理を行ったマウス胚性繊維芽細胞であり、誘導悪性幹細胞のピックアップ前日に5.0×104cell/cm2でゼラチンコート24ウェルプレートに播種した。
(i)0.25%トリプシン-1 mM EDTA溶液(インビトロジェン社製;Cat no.25200-056)
(ii)調製剥離液〔10 mg/mlタイプIVコラゲナーゼ(インビトロジェン社製;Cat no.17104-019)10 ml、100 mM塩化カルシウム溶液(シグマ)1 ml、PBS59 ml、2.5%トリプシン溶液(インビトロジェン社製;Cat no.15090-046)10 ml、ノックアウト血清リプレースメント(KSR, インビトロジェン社Catno.10828-028)20 ml;これらを溶解後、0.22μmのフィルターで濾過滅菌したもの〕。
(i)セルバンカー3(日本全薬工業Cat no.BLC-3S)
(ii)50%mTeSR1、40%KSR、10%DMSOの混液。
遺伝子導入後日数32: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数43: 6ウェルプレート(第2継代)→10 cm(第3継代)
遺伝子導入後日数50: 継代と保存(第4継代)
遺伝子導入後日数55: 継代と保存(第5継代)
遺伝子導入後日数58: バッファーRLT(RNA精製前の細胞溶解液)処理。
遺伝子導入後日数44: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数48: 6ウェルプレート(第2継代)→10 cm(第3継代)
遺伝子導入後日数53: 継代と保存(第4継代)
遺伝子導入後日数58: バッファーRLT(RNA精製前の細胞溶解液)処理。
遺伝子導入後日数44: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数52: 6ウェルプレート(第2継代)→10 cm(第3継代)
遺伝子導入後日数61: 継代と保存(第4継代)
遺伝子導入後日数63: 保存とバッファーRLT(RNA精製前の細胞溶解液)処理。
遺伝子導入後日数44: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数52: 6ウェルプレート(第2継代)→10 cm(第3継代)
遺伝子導入後日数61: 継代と保存(第4継代)
遺伝子導入後日数62: 保存とバッファーRLT(RNA精製前の細胞溶解液)処理。
遺伝子導入後日数44: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数48: 6ウェルプレート(第2継代)→10 cm(第3継代)
遺伝子導入後日数53: 継代と保存(第4継代)
遺伝子導入後日数55: 継代と保存(第5継代)
遺伝子導入後日数58: バッファーRLT(RNA精製前の細胞溶解液)処理。
保存液に数時間保存・運搬したヒト胃がん(進行がん)患者の新鮮非がん組織から細胞を単離し、初代培養した。得られた胃がん患者非がん組織由来の細胞に、実施例1において調製した3遺伝子(POU5F1、KLF4、SOX2の比率が順に4:2:1)レトロウイルスベクター液を添加し、遺伝子を導入することによって、ヒト誘導悪性幹細胞を作製した。詳細は以下の通りである。
それ以降、3日毎にMEF馴化ES培地の交換を続け、3遺伝子導入から31日後、mTeSR1で毎日培地交換を行った。遺伝子導入から41日後にコロニーを1クローン(NGC1-1)、ピックアップし、ゼラチンコート24ウェルプレート中のマイトマイシン処理を行ったマウス胚性繊維芽細胞上に継代した。なお、フィーダー細胞はマイトマイシン処理を行ったマウス胚性繊維芽細胞であり、誘導悪性幹細胞のピックアップ前日に5.0×104cell/cm2でゼラチンコート24ウェルプレートに播種した。
遺伝子導入後日数52: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数58: 6ウェルプレート(第2継代)→10 cm(第3継代)
遺伝子導入後日数65: 継代、保存、バッファーRLT(RNA精製前の細胞溶解液)処理。
保存液に数時間保存・運搬したヒト結腸がん患者の新鮮がん組織から細胞を単離した。得られたヒト結腸がん患者の新鮮がん組織由来の細胞に、実施例1において調製した3遺伝子(POU5F1、KLF4、SOX2の比率が順に4:2:1)レトロウイルスベクター液を添加し、遺伝子導入することで、ヒト誘導悪性幹細胞を作製した。詳細は以下の通りである。
その後、3日毎にMEF馴化ES培地の交換を続け、遺伝子導入22日後から、mTeSR1で毎日培地交換を行った。遺伝子導入から31日後に、コロニーの1クローン(CC1-10)をピックアップし、ゼラチンコート24ウェルプレート中のマイトマイシン処理を行ったマウス胚性繊維芽細胞に継代した。なお、フィーダー細胞はマイトマイシン処理を行ったマウス胚性繊維芽細胞であり、誘導悪性幹細胞のピックアップ前日に5.0×104cell/cm2でゼラチンコート24ウェルプレートに播種した。
CC1-10
遺伝子導入後日数49: 24ウェル(第1継代)→6ウェル(第2継代)
遺伝子導入後日数54: 6ウェル(第2継代)→10 cm(第3継代)
遺伝子導入後日数59: 継代と保存(第4継代)
遺伝子導入後日数63: 継代と保存(第5継代)
遺伝子導入後日数68: 一部をバッファーRLT(RNA精製前の細胞溶解液)処理
遺伝子導入後日数71: 一部をQiazol(RNA精製前の細胞溶解液)処理
遺伝子導入後日数75: 一部をNOD-SCIDマウスへ移植。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)により、ゲノムワイドな遺伝子発現(mRNAのトランスクリプトーム)を解析した。3種類のヒト胚性幹細胞hES_H9(GSM194390)、hES_BG03(GSM194391)及びhES_ES01(GSM194392)と、誘導多能性幹細胞hiPS-201B7(GSM241846)のマイクロアレイデーターは、GEOからダウンロードして使用した。
実施例2~4のヒト誘導悪性幹細胞(GC1-1、GC1-3、GC1-5、GC1-7、GC1-8、NGC1-1、CC1-10)のトータルRNAとゲノムDNAを、事前にバッファーRLT(RNA精製前の細胞溶解液)で処理した溶液から、AllPrep DNA/RNA Mini Kit(50)(キアゲン社製;Cat no.80204)を用いて抽出した。
(i)ゲノムDNAのクオリティーチェック
NanoDrop ND-1000(NanoDrop Technologies)で、DNA濃度及びDNAの純度の評価を行ったところ、何れのサンプルにおいても十分な濃度があり、純度も高いことが確認された。
RNA用LabChip(アジレント社製の登録商標)キットを用いて、Agilent 2100 Bioanalyzer(アジレント社製)でtotal RNAの品質のチェックを行ったところ、全てのRNAサンプルのクオリティーは良好であった。また、NanoDrop ND-1000(NanoDrop Technologies)で、RNA濃度及びRNAの純度の評価を行ったところ、何れのサンプルにおいてもcRNA合成に必要なtotalRNA量があることが確認され、純度も高いことが確認された。
各サンプルのtotalRNA(500 ng)から、Quick Amp Labeling kit(アジレント社製)を用いて、アジレント社のプロトコールに従って、2本鎖cRNAを合成した。作製したcDNAから、in vitro transcriptionによりcRNAを合成した。この際、Cyanine色素で標識されたCTP(Cyanine 3-CTP)を取り込ませ、蛍光標識を行った。
Gene Expression Hybridization Kit(アジレント社製)を使用して、ハイブリダイゼーション標識cRNAをハイブリダイゼーションバッファーに加え、アジレント製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)上で17時間ハイブリダイズし、洗浄後、アジレントマイクロアレイスキャナで、DNAマイクロアレイのイメージを読み取り、Feature Extraction Software(v.9.5.3.1)を用いて、各スポットの蛍光シグナルを数値化した。
解析ソフトとしては、GeneSpring GX10.0(アジレント・テクノロジー株式会社)を使用し、ノーマライゼーションは、50th percentileで行った。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された血管新生関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表34〔hES_BG03 vs GC1-5〕に記載した。更に、2倍以上発現上昇している血管新生関連遺伝子のプローブをプロットした図を示す(図1)。GC1-5はがん患者の新鮮がん組織(胃がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性のがん関連遺伝子である血管新生関連遺伝子(MDK遺伝子、TIMP2遺伝子、FGFR3遺伝子、PLAU遺伝子、ID3遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたがん関連パスウェイ遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)及びヒト誘導多能性幹細胞hiPS-201B7と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表35〔hES_H9 vs NGC1-1〕及び表36〔hiPS-201B7 vs NGC1-1〕にそれぞれ記載した。NGC1-1はがん患者の新鮮非がん組織(胃の非がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性のがん関連パスウェイ遺伝子(MMP2遺伝子、TIMP1遺伝子、TIMP3遺伝子、MMP1遺伝子、CDKN1A遺伝子、S100A4遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された間質バリア関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表37〔hES_BG03 vs GC1-5〕に記載した。GC1-5はがん患者の新鮮がん組織(胃がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性の間質バリア関連遺伝子(COL4A2遺伝子、FN1遺伝子、COL1A1遺伝子、TGFB1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された上皮-間葉転換関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、プローブ及びGenBankアクセッションナンバーを、下記表38〔hES_BG03 vs GC1-5〕に記載した。更に、2倍以上発現上昇している上皮-間葉転換関連遺伝子のプローブをプロットした図を示す(図2)。GC1-5はがん患者の新鮮がん組織(胃がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性の上皮-間葉転換関連遺伝子(VIM遺伝子、COL3A1遺伝子、COL1A2遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された胃がん関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表42〔hES_H9 vs NGC1-1〕に記載した。NGC1-1はがん患者の新鮮非がん組織(胃の非がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性の胃がん関連遺伝子(CCND2遺伝子、TIMP3遺伝子、LOX遺伝子、RASSF1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された自律増殖関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表43〔hES_H9 vs NGC1-1〕に記載した。NGC1-1はがん患者の新鮮非がん組織(胃の非がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性の自律増殖関連遺伝子(IGF2遺伝子、INHBA遺伝子、MDK遺伝子、INHBB遺伝子、BMP1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたTGFβ/BMPシグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_ES01(GSM194392)及びヒト誘導多能性幹細胞hiPS-201B7と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、それぞれ下記表44〔hES_ES01 vs GC1-5〕及び表45〔hiPS-201B7 vs GC1-5〕に記載した。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された組織侵潤・転移関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト誘導多能性幹細胞hiPS-201B7と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表50〔hiPS-201B7 vs GC1-5〕に記載した。GC1-5はがん患者の新鮮がん組織(胃がん組織)から調製した初代培養体(非胚性)細胞由来のヒト誘導悪性幹細胞であり、内在性の組織侵潤・転移関連遺伝子(FST遺伝子、BMP7遺伝子、TGFB1遺伝子、COL3A1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたWntシグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表52〔hES_H9 vs NGC1-1〕に記載した。更に、2倍以上発現上昇しているWntシグナル関連遺伝子のプローブをプロットした図を示す(図5)。誘導悪性幹細胞は内在性のWntシグナル関連遺伝子(CCND2遺伝子、SLC9A3R1遺伝子、LEF1遺伝子、CTNNB1遺伝子、FRZB遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたシグナル伝達関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表53〔hES_H9 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性のシグナル伝達関連遺伝子(CCL2遺伝子、CDKN1A遺伝子、HSPB1遺伝子、RBP1遺伝子、CCND1遺伝子、LEF1遺伝子、GADD45A遺伝子、BAX遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたNotchシグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表54〔hES_H9 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性のNotchシグナル関連遺伝子(CD44遺伝子、FZD2遺伝子、CCND1遺伝子、HES1遺伝子、CDKN1A遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された乳がん及びエストロジェン受容体シグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表55〔hES_H9 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性の乳がん及びエストロジェン受容体シグナル関連遺伝子(KRT18遺伝子、KRT19遺伝子、GSN遺伝子、TFF1遺伝子、CTSB遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された結腸がん関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表56〔hES_H9 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性の結腸がん関連遺伝子(DKK3遺伝子、SPARC遺伝子、IGF2遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された低酸素シグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表57〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性の低酸素シグナル関連遺伝子(EPAS1遺伝子、TUBA4遺伝子、EEF1A1遺伝子、CDC42遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたGPCRシグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表58〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性のGPCRシグナル関連遺伝子(GNAS遺伝子、RGS2遺伝子、JUNB遺伝子、AGT遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された薬剤耐性関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表59〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性の薬剤耐性関連遺伝子(AQP1遺伝子、SLC16A3遺伝子、ATP6V0C遺伝子、MVP遺伝子、ABCG2遺伝子、ATP7B遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたHedgehogシグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表60〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性のHedgehogシグナル関連遺伝子(CTNNB1遺伝子、FGFR3遺伝子、ERBB4遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたPI3K-AKTシグナル関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表61〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性のPI3K-AKTシグナル関連遺伝子(HSPB1遺伝子、ITGB1遺伝子、CTNNB1遺伝子、PDGFRA遺伝子、FKBP1A遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された薬物代謝遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表62〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性の薬物代謝遺伝子(PKM2遺伝子、GSTM3遺伝子、COMT遺伝子、ALDH1A1遺伝子、BLVRB遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたがん分子メカニズム遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト誘導多能性幹細胞hiPS-201B7と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表63〔hiPS-201B7 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性のがん分子メカニズム遺伝子(BAX遺伝子、NFKBIA遺伝子、BCL2遺伝子、CASP8遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたSMADシグナルネットワーク関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_ES01(GSM194392)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表64〔hES_ES01 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性のSMADシグナルネットワーク関連遺伝子(PSMC3遺伝子、HDAC5遺伝子、UBB遺伝子、ACTA2遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された膵がん関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト誘導多能性幹細胞hiPS-201B7と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表65〔hiPS-201B7 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性の膵がん関連遺伝子を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された前立腺がん関連遺伝子のプローブの内、本発明の本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表66〔hES_BG03 vs NGC1-1〕に記載した。誘導悪性幹細胞は内在性の前立腺がん関連遺伝子(SFRP1遺伝子、TIMP2遺伝子、DKK3遺伝子、DLC1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された肝がん関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表67〔hES_BG03 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性の肝がん関連遺伝子(CCND2遺伝子、DLC1遺伝子、CDKN1A遺伝子、DAB2IP遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された肺がん関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表68〔hES_BG03 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性の肺がん関連遺伝子(CDKN1C遺伝子、MGMT遺伝子、RASSF2遺伝子、CADM1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたストレス及び毒性関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表69〔hES_H9 vs GC1-5〕に記載した。誘導悪性幹細胞は内在性のストレス及び毒性関連遺伝子(GDF15遺伝子、GSTM3遺伝子、HMOX1遺伝子、HSPA5遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたエピジェネティクスクロマチン修飾酵素遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表70〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞はエピジェネティクスクロマチン修飾酵素遺伝子(HDAC5遺伝子、SMYD3遺伝子、HDAC10遺伝子、PRMT5遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された幹細胞転写因子遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1がヒト胚性幹細胞hES_H9(GSM194390)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表71〔hES_H9 vs NGC1-1〕に記載した。誘導悪性幹細胞は幹細胞転写因子遺伝子(NR2F2遺伝子、PITX2遺伝子、HAND1遺伝子、ZIC1遺伝子)を相対的に高発現していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された肝細胞関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_BG03(GSM194391)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表72〔hES_BG03 vs GC1-5〕に記載した。誘導悪性幹細胞は1)~31)の何れかに加えて肝細胞関連遺伝子(TTR遺伝子、DLK1遺伝子、AFP遺伝子、TF遺伝子)がヒト胚性幹細胞hES_H9(GSM194390)と比較して相対的に高発現上昇していることが明らかとなった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された自己複製関連遺伝子のプローブの内、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5がヒト胚性幹細胞hES_H9(GSM194390)と比較してほぼ同程度(1/2から2倍)発現している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表73〔hES_H9 = GC1-5〕に記載した。更に、本発明のヒト誘導内胚葉系悪性幹細胞NGC1-1とヒト胚性幹細胞hES_BG03(GSM194391)を比較して、ほぼ同程度(1/2から2倍)発現している自己複製関連遺伝子のプローブをプロットしたグラフを(図6)示す。なお、表1の自己複製関連遺伝子の全てが、本発明のヒト誘導内胚葉系悪性幹細胞GC1-5とヒト胚性幹細胞hES_H9(GSM194390)と比較してほぼ同程度(1/8から8倍)発現していた。
実施例3の誘導悪性幹細胞(NGC1-1)について、Gバンド分染法によって20細胞/株、モード分析により50細胞/株について、核型、染色体の本数を検査した。その結果、これら誘導悪性幹細胞は全て46XYの核型であり、正常であった。誘導悪性幹細胞(NGC1-1:遺伝子導入後日数76)は、MEFの上でmTeSR1などを用いて培養した細胞を解析した。誘導悪性幹細胞は核型が正常な細胞であった。
実施例3の誘導悪性幹細胞(NGC1-1)について、マルチカラーFISHによって10細胞/株について、染色体の欠失、転座を検査した。その結果、これら誘導悪性幹細胞は全て染色体が正常であった(異常が検出されなかった)。誘導悪性幹細胞(NGC1-1:遺伝子導入後日数76)は、MEFの上でmTeSR1を用いて培養した細胞を解析した。誘導悪性幹細胞は染色体異常(染色体の転座、欠失)がない細胞であった。
誘導悪性幹細胞(NGC1-1)の培養上清を臨床検査会社SRLに解析依頼した結果、誘導悪性幹細胞はTGFβ1、AFP、プロコラ-ゲンIIIペプチド(P-III-P)、IV型コラーゲン、アポリポタンパクC-II、プレアルブミン(TTR)、IGF-Iタンパク質を産生していることが判明した。この結果から、誘導悪性幹細胞は、腫瘍マーカーを産生する細胞であることが判明した。
実施例3の誘導悪性幹細胞(NGC1-1)をマウスに移植して、悪性細胞から誘導されたがん細胞の組織像の観察と担がんモデルの作製のため以下の実験を行った。
実施例3の誘導悪性幹細胞(GC1-2、NGC1-1)を古河電気工業製のPERFLOWTM Sortにより、1細胞/ウェルで96ウェルプレートにシングルソーテイングした。その結果、モノクローナルな誘導悪性幹細胞(GC1-2-1、GC1-2-2、GC1-2-3、GC1-2-4、NGC1-1-1、NGC1-1-2、NGC1-1-3、NGC1-1-4)が樹立された。
CD34(Alexa fluor 488-conjugatedマウスモノクローナル抗体 anti-human CD34;Biolegend社製;clone:581;mouseIgG1))、VEGFR2(Alexa fluor 647-conjugatedマウスモノクローナル抗体 anti-human CD309;Biolegend社製;clone:HKDR-1;mouseIgG1))、PDGFRα(PE-conjugated anti-human CD140a;Biolegend社製;clone:16A1;mouseIgG1)、DLK-1(マウスモノクローナル抗体 anti-human Pref-1/DLK-1/FA1;R&D社製;clone#:MAB1144;mouseIgG2B)、CXCR4(Carboxyfluorescein(CFS)-conjugatedマウスモノクローナル抗体 anti-human CXCR4;R&D社製;clone#:12G5;mouseIgG2A)、E-カドヘリン(APC-conjugated anti-human CD324;Biolegend社製;clone:67A4;mouseIgG1)、IGF-R1(マウスモノクローナル抗体 anti-human IGF-IR;R&D社製;clone#:MAB391;mouseIgG1)、FABP1(マウスモノクローナル抗体 anti-human FABP1;R&D社製;clone#:MAB2964;mouseIgG2a)、ALB(マウスモノクローナル抗体 anti-human serum albumin;SIGMA社製;clone:HAS-11;mouseIgG2a)で染色し、実施例3の誘導悪性幹細胞(NGC1-1)を古河電気工業のPERFLOWTMSortにより、染色陽性率を計測した。陽性率が高い場合は、陽性画分を1細胞/ウェルで96ウェルプレートにシングルソーテイングした。
実施例1と同様に、POU5F1>SOX2の関係になるようレトロウイルスベクター液を調整した。詳細は、以下の通りである
<家族性大腸ポリポーシス(APC)患者皮膚組織由来の細胞へ遺伝子導入するレトロウイルスベクター液の調製>
遺伝子POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは、構築したベクターである(前記表33)。
遺伝子POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは、構築したベクターである(前記表33)。
遺伝子POU5F1-pMXs、KLF4-pMXs、SOX2-pMXsは、構築したベクターである(前記表33)。
POU5F1-KLF4-SOX2-pMXs 8.4 kbは、pCX-OKS-2A(8478 bp)のEcoRI-EcoRIインサート部分(3700 bp)を切り出し、pMXs(5871 bp)のEcoRI-EcoRI部分(1122 bp)と組み換えて構築したベクターである。さらに、5'末端から3'末端方向へ順向きであること確認した。(下記表76)。
APC患者(APC3223、25才、男性、白人、541番目のグルタミン[541 Gln、Q:CAA or CAG]のC塩基がT塩基に置換して終止コドンになる)の皮膚組織(凍結した継代数:2)の体細胞から、内在性がん抑制遺伝子であるAPCの変異を有するヒト誘導内胚葉系前がん幹細胞を以下のように樹立した。凍結保存された家族性大腸腺腫症患者の、皮膚組織に由来する細胞のバイアル1本(米国NPO Coriell Institute for Medical Research;Cat no.GM03223)を、37℃の恒温槽中で解凍し、1×抗生物質-抗真菌剤及びFBSを10%含むD-MEM(高グルコース)培地に懸濁し、10 mlの細胞懸濁液を得た。家族性大腸腺腫症(APC)患者の皮膚組織由来の細胞は、生殖系列(遺伝的)に片側アリルのAPCに変異(541 Gln→ter:C→T)をもつ、前がん細胞である。
APC(3223)1-1
遺伝子導入後日数54: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数60: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数67: 継代(第4継代)と保存
遺伝子導入後日数72: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存(第5継代)。
遺伝子導入後日数59: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数75: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数79: 保存。
遺伝子導入後日数59: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数75: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数79: 保存。
遺伝子導入後日数59: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数75: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数79: 保存。
APC患者(APC3946、22才、女性、白人、541番目のグルタミン[541 Gln、Q:CAA or CAG]のC塩基がT塩基に置換して終止コドンになる。前述のAPC3223とは兄弟関係である。)の皮膚組織(凍結した継代数:2)から、ヒト誘導内胚葉系前がん幹細胞を以下のように樹立した。凍結保存された家族性大腸腺腫症患者の皮膚組織由来の細胞のバイアル1本(CORIELL;Cat no.GM03946)を、37℃の恒温槽中で解凍し、1×抗生物質-抗真菌剤及びFBSを10%含むD-MEM(高グルコース)培地に懸濁し、10 mlの細胞懸濁液を得た。
APC(3946)1-1
遺伝子導入後日数54: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数61: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数72: 継代(第4継代)と保存
遺伝子導入後日数77: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存(第5継代)。
遺伝子導入後日数59: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数61: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数72: 継代(第4継代)と保存
遺伝子導入後日数77: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存(第5継代)。
RB患者(1才、男性、日本人、RB1の706番目のコドン[706:TGT]のG塩基がA塩基に置換している)の皮膚組織(継代数3)から、内在性がん抑制遺伝子の変異を有するヒト誘導前がん幹細胞を以下のように樹立した。凍結保存された網膜芽腫患者の皮膚組織由来の細胞1本(医薬基盤研究所;資源番号:KURB2358ロット番号:080786)を、37℃の恒温槽中で解凍し、1×抗生物質-抗真菌剤及びFBSを10%含むD-MEM(高グルコース)培地に懸濁し、10 mlの細胞懸濁液を得た。
RB(203)1-2
遺伝子導入後日数49: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数77: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数82: 保存。
遺伝子導入後日数49: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数77: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数82: 保存。
遺伝子導入後日数53: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数60: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数66: 継代(第4継代)と保存
遺伝子導入後日数69: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存。
遺伝子導入後日数53: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数59: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数63: 継代(第4継代)と保存
遺伝子導入後日数66: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存。
遺伝子導入後日数56: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数77: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数82: 保存。
遺伝子導入後日数56: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数77: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数82:保存。
遺伝子導入後日数56: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数59: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数82: 保存。
家族性腫瘍患者であるRB患者(1歳、男性、日本人、RB1遺伝子の706番目のコドン(706:TGT)のG塩基がA塩基に置換している)のがん組織(網膜芽細胞腫)から、内在性がん抑制遺伝子の変異を有するヒト誘導悪性幹細胞を以下のように樹立した。凍結保存された網膜芽腫患者の網膜芽細胞腫の凍結バイアル1本(医薬基盤研究所;資源番号:KURB2359ロット番号:091285)を、37℃の恒温槽中で解凍し、1×抗生物質-抗真菌剤及びFBSを10%含むD-MEM(高グルコース)培地に懸濁し、10 mlの細胞懸濁液を得た。
RBT203(1-1)
遺伝子導入後日数28: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数33: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数38: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存。
遺伝子導入後日数32: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数56: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数61: 保存。
遺伝子導入後日数32: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数56: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数61: 保存。
遺伝子導入後日数32: ウェルプレート(第1継代)→ウェルプレート(第2継代)
遺伝子導入後日数39: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数45: 継代と保存
遺伝子導入後日数48: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存。
遺伝子導入後日数32: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数39: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数45: 継代と保存
遺伝子導入後日数48: バッファーRLT(RNA精製前の細胞の溶解液)処理と保存。
RB患者(2才、女性、日本人)の皮膚組織(継代数1)から、ヒト誘導前がん幹細胞を以下のように樹立した。凍結保存された網膜芽腫患者の皮膚組織由来の体細胞1本(医薬基盤研究所;資源番号:KURB2435ロット番号:080687)を、37℃の恒温槽中で解凍し、1×抗生物質-抗真菌剤及びFBSを10%含むD-MEM(高グルコース)培地に懸濁し、20 mlの細胞懸濁液を得た。
RB(243)1-1
遺伝子導入後日数61: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数65: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数74: 保存。
遺伝子導入後日数61: 24ウェルプレート(第1継代)→6ウェルプレート(第2継代)
遺伝子導入後日数65: 6ウェルプレート(第2継代)→10 cm培養皿(第3継代)
遺伝子導入後日数74: 保存。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)を用いて、ヒト誘導悪性幹細胞(RBT203(1-1))の解析を行った。解析ソフトは、GeneSpring GX 10.0を使用し、ノーマライゼーションは、50th percentileで行った。実験手法は実施例5と同様である。
実施例16のヒト誘導悪性幹細胞(RBT203(1-1))のトータルRNAとゲノムDNAを、事前にバッファーRLT(RNA精製前の細胞溶解液)で処理した溶液から、AllPrep DNA/RNA Mini Kit(50)(キアゲン社製;Cat no.80204)を用いて抽出した。
NanoDrop ND-1000(NanoDrop Technologies)で、DNA濃度及びDNAの純度の評価を行ったところ、何れのサンプルにおいても十分な濃度があり、純度も高いことが確認された。
RNA用LabChip(アジレント社製の登録商標)キットを用いて、Agilent 2100 Bioanalyzer(アジレント社製)でtotal RNAの品質のチェックを行ったところ、全てのRNAサンプルのクオリティーは良好であった。また、NanoDrop ND-1000(NanoDrop Technologies)で、RNA濃度及びRNAの純度の評価を行ったところ、何れのサンプルにおいてもcRNA合成に必要なtotal RNA量があることが確認され、純度も高いことが確認された。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された血管新生関連遺伝子のプローブの内、本発明のヒト誘導悪性幹細胞RBT203(1-1)がヒト胚性幹細胞hES_ES01(GSM194392)と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表77〔hES_ES01 vs RBT203(1-1)〕に記載した。更に、2倍以上発現上昇している血管新生関連遺伝子のプローブをプロットした図を示す(図9)。以上から、ヒト誘導悪性幹細胞は血管新生関連遺伝子を2倍以上発現上昇している細胞であることが明らかになった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載されたシグナル伝達関連遺伝子のプローブの内、ヒト誘導悪性幹細胞RBT203(1-1)がヒト誘導多能性幹細胞hiPS-201B7と比較して2倍以上発現上昇している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表78〔hiPS-201B7 vs RBT203-1-1〕に記載した。更に、2倍以上発現上昇しているシグナル伝達関連遺伝子のプローブをプロットした図を示す(図10)。以上から、ヒト誘導悪性幹細胞はシグナル伝達関連遺伝子を2倍以上発現上昇している細胞であることが明らかになった。
アジレント社製Whole Human GenomeオリゴDNAマイクロアレイ(4X44K)に搭載された自己複製関連遺伝子のプローブの内、ヒト誘導悪性幹細胞RBT203(1-1)がヒト胚性幹細胞hES_ES01(GSM194392)と比較してほぼ同程度(1/2から2倍)発現している遺伝子の遺伝子シンボル、GenBankアクセッションナンバー及びプローブを、下記表79〔hES_ES01=RBT203-1-1〕に記載した。更に、ほぼ同程度(1/2から2倍)発現している自己複製関連遺伝子のプローブをプロットしたグラフを(図11)示す。
Claims (20)
- 少なくとも、下記(1)および(2)の要件:
(1)POU5F1遺伝子、NANOG遺伝子、SOX2遺伝子、ZFP42遺伝子、LIN28遺伝子及びTERT遺伝子の6遺伝子を発現すること;
(2)(a)内在性がん抑制遺伝子の変異、または(b)内在性がん関連遺伝子の発現上昇のいずれかの異常を有すること;
を具備することを特徴とする、誘導前がん幹細胞又は誘導悪性幹細胞である誘導がん幹細胞。 - 前記誘導がん幹細胞で発現している前記(1)自己複製関連遺伝子の発現量が、胚性幹細胞で発現している遺伝子の発現量と比較して1/8から8倍である、請求項1に記載された誘導がん幹細胞。
- 誘導前がん幹細胞である、請求項1または2に記載の誘導がん幹細胞。
- (a)前記がん抑制遺伝子が、APC遺伝子、またはRB1遺伝子である、請求項3に記載された誘導がん幹細胞。
- 誘導悪性幹細胞である、請求項1または2に記載の誘導がん幹細胞。
- (b)前記がん関連遺伝子が、血管新生関連遺伝子群、がん関連パスウェイ遺伝子群、間質バリア関連遺伝子群、上皮-間葉転換関連遺伝子群、胃がん関連遺伝子群、自律増殖関連遺伝子群、TGFβ/BMPシグナル関連遺伝子群、組織侵潤・転移関連遺伝子群、Wntシグナル関連遺伝子群、シグナル伝達関連遺伝子群、Notchシグナル関連遺伝子群、乳がん及びエストロジェン受容体シグナル関連遺伝子群、結腸がん関連遺伝子群、低酸素シグナル関連遺伝子群、GPCRシグナル関連遺伝子群、薬剤耐性関連遺伝子群、Hedgehogシグナル関連遺伝子群、PI3K-AKTシグナル関連遺伝子群、薬物代謝遺伝子群、がん分子メカニズム遺伝子群、SMADシグナルネットワーク関連遺伝子群、膵がん関連遺伝子群、前立腺がん関連遺伝子群、肝がん関連遺伝子群、肺がん関連遺伝子群からなる群に含まれる遺伝子の群の中から選択される少なくとも1種の遺伝子群である、請求項5に記載された誘導がん幹細胞。
- (b)前記内在性がん関連遺伝子に加え、ストレス及び毒性関連遺伝子群、エピジェネティクスクロマチン修飾酵素遺伝子群、幹細胞転写因子遺伝子群からなる群に含まれる遺伝子の群の中から選択される少なくとも1種の内在性の遺伝子に、遺伝子の発現上昇が生じている、請求項5または6に記載された誘導がん幹細胞。
- (b)前記内在性がん関連遺伝子に加え、肝細胞特異的遺伝子群に含まれる遺伝子の群の中から選択される少なくとも1種の遺伝子に、遺伝子の発現上昇が生じている、請求項5~7の何れかに記載された誘導がん幹細胞。
- 更に、中内胚葉系幹細胞、または内胚葉系幹細胞に特徴的な遺伝子を発現している、請求項5~8の何れかに記載された誘導がん幹細胞。
- 前記中内胚葉系幹細胞に特徴的な遺伝子がGSC遺伝子であり、前記内胚葉系幹細胞に特徴的な遺伝子が、GSC遺伝子、GATA4遺伝子、FOXA2遺伝子、SOX17遺伝子から選択された少なくとも1種である、請求項9に記載された誘導がん幹細胞。
- (a)内在性がん抑制遺伝子の変異を有する哺乳動物から採取した体細胞、並びに、発がんした哺乳動物から採取した、非胚性の原料体細胞から、請求項1の(1)および(2)の特徴を有する誘導がん幹細胞を製造する方法であって、該方法が、前記原料体細胞を、POU5F1遺伝子、KLF4遺伝子及びSOX2遺伝子の遺伝子産物が前記原料体細胞内に存在する状態におく誘導工程を行うことを特徴とする、誘導前がん幹細胞又は誘導悪性幹細胞である誘導がん幹細胞の製造方法。
- POU5F1遺伝子、KLF4遺伝子及びSOX2遺伝子の遺伝子産物の前記原料体細胞内における存在比率が、POU5F1遺伝子>SOX2遺伝子の関係を満たす、請求項11に記載された誘導がん幹細胞の製造方法。
- POU5F1遺伝子、KLF4遺伝子及びSOX2遺伝子又はこれらの遺伝子産物を使用する、請求項11または12に記載されたの製造方法。
- 更に、1ウェルに1細胞をソーティングして増殖させる工程を含む、請求項11~13の何れかに記載された製造方法。
- 更に、in vitroで自己複製可能な誘導がん幹細胞の悪性の性質又は特異マーカーを同定して選別する選別工程を含む、請求項11~14の何れかに記載された製造方法。
- 前記選別工程が、(a)内在性がん抑制遺伝子の変異を有する哺乳動物から採取した体細胞、並びに、発がんした哺乳動物から採取した、非胚性の原料体細胞を誘導処理した細胞と、比較対象となる哺乳動物から採取した体細胞から誘導した、誘導中内胚葉系幹細胞、誘導内胚葉系幹細胞又は誘導多能性幹細胞、若しくは、胚性幹細胞と比較し、悪性の性質又は特異マーカーを同定して選別する選別工程である、請求項15に記載された製造方法。
- 前記選別工程が、血管新生関連遺伝子群、がん関連パスウェイ遺伝子群、間質バリア関連遺伝子群、上皮-間葉転換関連遺伝子群、胃がん関連遺伝子群、自律増殖関連遺伝子群、TGFβ/BMPシグナル関連遺伝子群、組織侵潤・転移関連遺伝子群、Wntシグナル関連遺伝子群、シグナル伝達関連遺伝子群、Notchシグナル関連遺伝子群、乳がん及びエストロジェン受容体シグナル関連遺伝子群、結腸がん関連遺伝子群、低酸素シグナル関連遺伝子群、GPCRシグナル関連遺伝子群、薬剤耐性関連遺伝子群、Hedgehogシグナル関連遺伝子群、PI3K-AKTシグナル関連遺伝子群、薬物代謝遺伝子群、がん分子メカニズム遺伝子群、SMADシグナルネットワーク関連遺伝子群、膵がん関連遺伝子群、前立腺がん関連遺伝子群、肝がん関連遺伝子群、肺がん関連遺伝子群からなる群に含まれる遺伝子の群の中から選択される、少なくとも1種の遺伝子に係るがん関連遺伝子の発現上昇から同定し選別する選別工程である、請求項15または16に記載された製造方法。
- がん創薬標的のスクリーニング方法、がん治療薬のスクリーニング方法及びがん診断薬のスクリーニング方法の中から選択された1種のスクリーニング方法であって、該方法が、請求項1~10の何れかに記載された誘導がん幹細胞を用いることを特徴とする、スクリーニング方法。
- 請求項1~10の何れかに記載された誘導がん幹細胞を用いることを特徴とする、がんワクチンの作製方法。
- 請求項1~10の何れかに記載された誘導がん幹細胞を実験動物に移植することを特徴とする、がんモデル動物の作製方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11786682.2A EP2599860A4 (en) | 2010-05-25 | 2011-05-25 | INDUCED MALIGNE STEM CELLS OR FOR SELF-REPLICATION OUTSIDE OF AN ORGANISM CAPABLE, PRESENTATION METHOD AND MANUFACTURING METHOD THEREFOR |
CA2804119A CA2804119A1 (en) | 2010-05-25 | 2011-05-25 | Induced malignant stem cells or pre-induction cancer stem cells capable of self-replication outside of an organism, production method for same, and practical application for same |
CN2011800259608A CN102906249A (zh) | 2010-05-25 | 2011-05-25 | 能够在体外自我复制的诱导性前癌干细胞或诱导性恶性干细胞,这些细胞的制备方法,及这些细胞的应用 |
US13/699,431 US20130198876A1 (en) | 2010-05-25 | 2011-05-25 | Induced malignant stem cells or pre-induction cancer stem cells capable of selfreplication outside of an organism, production method for same, and practical application for same |
JP2012517298A JP5920725B2 (ja) | 2010-05-25 | 2011-05-25 | 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 |
KR1020127032359A KR20130080444A (ko) | 2010-05-25 | 2011-05-25 | 생체 외에서 자기 복제 가능한 유도 전암 간세포 또는 유도 악성 간세포, 이들의 제조 방법, 및, 이들 세포의 응용 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010119385 | 2010-05-25 | ||
JP2010-119385 | 2010-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011148983A1 true WO2011148983A1 (ja) | 2011-12-01 |
Family
ID=45003972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/062006 WO2011148983A1 (ja) | 2010-05-25 | 2011-05-25 | 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130198876A1 (ja) |
EP (1) | EP2599860A4 (ja) |
JP (1) | JP5920725B2 (ja) |
KR (1) | KR20130080444A (ja) |
CN (1) | CN102906249A (ja) |
CA (1) | CA2804119A1 (ja) |
WO (1) | WO2011148983A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012165287A1 (ja) * | 2011-05-27 | 2012-12-06 | 公立大学法人横浜市立大学 | 人工癌幹細胞の作製方法及びその分化誘導方法 |
WO2013081188A1 (ja) * | 2011-11-30 | 2013-06-06 | 独立行政法人国立がん研究センター | 誘導悪性幹細胞 |
JP2013208104A (ja) * | 2012-03-02 | 2013-10-10 | Yamaguchi Univ | 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法 |
WO2013168644A1 (ja) * | 2012-05-11 | 2013-11-14 | 独立行政法人国立がん研究センター | 腎細胞癌の予後予測方法 |
JP2015033381A (ja) * | 2013-07-10 | 2015-02-19 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
JP2018506278A (ja) * | 2015-01-30 | 2018-03-08 | センター ナショナル ド ラ ルシェルシュ サイエンティフィーク | デルタ133p53ベータおよびデルタ133p53ガンマアイソフォームはがん幹細胞のバイオマーカーである |
CN107921173A (zh) * | 2015-08-03 | 2018-04-17 | 富士胶片株式会社 | 细胞结构体、非人模型动物、非人模型动物的制造方法及被检验物质的评价方法 |
CN111073889A (zh) * | 2019-12-20 | 2020-04-28 | 中国人民解放军第四军医大学 | 人cspg5基因的用途及相关产品 |
CN115840045A (zh) * | 2023-02-23 | 2023-03-24 | 中国农业大学 | 一种猪胚胎期毛囊基板前体细胞的鉴定方法及其应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015175500A2 (en) * | 2014-05-12 | 2015-11-19 | The Scripps Research Institute | Methods for modulating cancer cells and stem cells |
SG11201701728PA (en) * | 2014-09-04 | 2017-04-27 | Agency Science Tech & Res | A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells |
EP3135768A1 (en) * | 2015-08-26 | 2017-03-01 | Self-screen B.V. | Zic1 and ghsr, molecular diagnostic markers for hpv-induced invasive cancers, nonhpv-induced gynaecological and anogenital cancers and their high-grade precursor lesions |
GB201520550D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
CN106676073A (zh) * | 2017-01-19 | 2017-05-17 | 大连医科大学附属第医院 | 一种乳腺癌mcf‑7细胞干细胞悬浮球的培养方法 |
WO2019101956A1 (en) | 2017-11-24 | 2019-05-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for treating cancers |
SI3794148T1 (sl) * | 2018-05-17 | 2022-11-30 | Twobull Meditherapy P. C. | Postopki za diagnostiko anevrizme ali raka |
CN111635912A (zh) * | 2020-06-18 | 2020-09-08 | 深圳市体内生物医药科技有限公司 | 一种将肝细胞诱导为肝癌细胞的基因组合及其应用 |
CN112266932B (zh) * | 2020-10-19 | 2023-06-02 | 天津科技大学 | 一种人rnf20基因过表达质粒载体的构建及其抑制癌细胞的作用 |
CN114276999A (zh) * | 2022-03-03 | 2022-04-05 | 中日友好医院(中日友好临床医学研究所) | 黑素瘤细胞株及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3229590B2 (ja) | 1993-01-14 | 2001-11-19 | 佑 本庶 | cDNAライブラリーの作製方法およびポリペプチドのスクリーニング方法 |
JP3499528B2 (ja) | 1997-11-26 | 2004-02-23 | 中外製薬株式会社 | シグナルシーケンストラップ法 |
JP2008283972A (ja) | 2005-12-13 | 2008-11-27 | Kyoto Univ | 誘導多能性幹細胞の製造方法 |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101617043B (zh) * | 2007-10-31 | 2014-03-12 | 国立大学法人京都大学 | 核重编程方法 |
GB0801215D0 (en) * | 2008-01-23 | 2008-02-27 | Univ Sheffield | Cell re-programming |
CN101550406B (zh) * | 2008-04-03 | 2016-02-10 | 北京大学 | 制备多潜能干细胞的方法,试剂盒及用途 |
EP3075850B1 (en) * | 2008-07-16 | 2019-02-06 | ID Pharma Co., Ltd. | Method for production of reprogrammed cell using chromosomally unintegrated virus vector |
WO2011049099A1 (ja) * | 2009-10-20 | 2011-04-28 | 国立大学法人大阪大学 | 癌幹細胞の製造方法 |
-
2011
- 2011-05-25 KR KR1020127032359A patent/KR20130080444A/ko not_active Application Discontinuation
- 2011-05-25 CA CA2804119A patent/CA2804119A1/en not_active Abandoned
- 2011-05-25 JP JP2012517298A patent/JP5920725B2/ja active Active
- 2011-05-25 WO PCT/JP2011/062006 patent/WO2011148983A1/ja active Application Filing
- 2011-05-25 EP EP11786682.2A patent/EP2599860A4/en not_active Withdrawn
- 2011-05-25 CN CN2011800259608A patent/CN102906249A/zh active Pending
- 2011-05-25 US US13/699,431 patent/US20130198876A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3229590B2 (ja) | 1993-01-14 | 2001-11-19 | 佑 本庶 | cDNAライブラリーの作製方法およびポリペプチドのスクリーニング方法 |
JP3499528B2 (ja) | 1997-11-26 | 2004-02-23 | 中外製薬株式会社 | シグナルシーケンストラップ法 |
JP2008283972A (ja) | 2005-12-13 | 2008-11-27 | Kyoto Univ | 誘導多能性幹細胞の製造方法 |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
Non-Patent Citations (25)
Title |
---|
"Center for iPS Cell Research and Application", vol. 7.4, 2008, INSTITUTE FOR INTEGRATED CELL-MATERIAL SCIENCE, article "Methods of establishing human iPS cells", pages: 1 - 14 |
BAE, KM ET AL.: "Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.", J UROL., vol. 183, no. 5, May 2010 (2010-05-01), pages 2045 - 2053, XP027038755 * |
CARETTE JE ET AL., BLOOD, vol. 115, 2010, pages 4039 - 4042 |
ERRATUM IN SCIENCE, vol. 282, no. 5395, 4 December 1998 (1998-12-04), pages 1827 |
HIROFUMI SUEMORI ET AL.: "Efficient establishment of human embryonic stem cell lines and long term maintenance with stable karyotype by enzymatic bulk passage", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 345, 2006, pages 926 - 32 |
HOCHEDLINGER K; JAENISCH R ET AL., GENES DEV., vol. 18, 2004, pages 1875 - 1885 |
ILIOPOULOS, D ET AL.: "Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.", PROC NATL ACAD SCI U S A., vol. 108, no. 4, 25 January 2011 (2011-01-25), pages 1397 - 1402, XP055098845 * |
INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH, 2009, pages 285 |
JOURNAL OF VIROLOGY, vol. 72, 1998, pages 8150 - 8157 |
LEE, JS ET AL.: "Brain cancer stem-like cell genesis from p53-deficient mouse astrocytes by oncogenic Ras.", BIOCHEM BIOPHYS RES COMMUN., vol. 365, no. 3, 18 January 2008 (2008-01-18), pages 496 - 502, XP022372609 * |
MASAKI H; ISHIKAWA T ET AL., STEM CELL RES., vol. 1, 2008, pages 105 - 115 |
MIYOSHI, N ET AL.: "Defined factors induce reprogramming of gastrointestinal cancer cells.", PROC NATL ACAD SCI U S A., vol. 107, no. 1, 5 January 2010 (2010-01-05), pages 40 - 45, XP055083357 * |
NAGAI K ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 395, 2010, pages 258 - 263 |
NAKAGAWA M; YAMANAKA S ET AL., NAT BIOTECHNOL., vol. 26, 2008, pages 101 - 106 |
NUCLEIC ACIDS RES., vol. 23, 1995, pages 3816 - 3821 |
NUCLEIC ACIDS RESEARCH, vol. 18, 1990, pages 3587 - 3596 |
PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 6733 - 6737 |
See also references of EP2599860A4 |
TAKAHASHI K; YAMANAKA S ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI K; YAMANAKA S, CELL, vol. 131, 2007, pages 861 - 872 |
THOMSON JA ET AL.: "Embryonic stem cell lines derived from human blastocysts", SCIENCE, vol. 282, no. 5391, 6 November 1998 (1998-11-06), pages 1145 - 7, XP002933311, DOI: doi:10.1126/science.282.5391.1145 |
TOSHIO KITAMURA: "Retrovirus-mediated gene transfer and expression cloning: Powerful tools in functional genomics", EXPERIMENTAL HEMATOLOGY, vol. 31, no. 11, 2003, pages 1007 - 14, XP009118675, DOI: doi:10.1016/j.exphem.2003.07.005 |
UTIKAL J ET AL., J CELL SCI., vol. 122, 2009, pages 3502 - 3510 |
VISVADER JE; LINDEMAN GJ, NAT REV CANCER., vol. 8, 2008, pages 755 - 768 |
XU, Q ET AL.: "Isolation of tumour stem-like cells from benign tumours.", BR J CANCER., vol. 101, no. 2, 21 July 2009 (2009-07-21), pages 303 - 311, XP055098334 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012165287A1 (ja) * | 2011-05-27 | 2012-12-06 | 公立大学法人横浜市立大学 | 人工癌幹細胞の作製方法及びその分化誘導方法 |
US10731134B2 (en) | 2011-05-27 | 2020-08-04 | Public University Corporation Yokohama City University | Production method for artificial cancer stem cell and induced differentiation method therefor |
WO2013081188A1 (ja) * | 2011-11-30 | 2013-06-06 | 独立行政法人国立がん研究センター | 誘導悪性幹細胞 |
JP2013208104A (ja) * | 2012-03-02 | 2013-10-10 | Yamaguchi Univ | 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法 |
JP2018139601A (ja) * | 2012-05-11 | 2018-09-13 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
WO2013168644A1 (ja) * | 2012-05-11 | 2013-11-14 | 独立行政法人国立がん研究センター | 腎細胞癌の予後予測方法 |
JPWO2013168644A1 (ja) * | 2012-05-11 | 2016-01-07 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
JP2018148900A (ja) * | 2012-05-11 | 2018-09-27 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
JP2018139600A (ja) * | 2012-05-11 | 2018-09-13 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
JP2018139599A (ja) * | 2012-05-11 | 2018-09-13 | 国立研究開発法人国立がん研究センター | 腎細胞癌の予後予測方法 |
JP2015033381A (ja) * | 2013-07-10 | 2015-02-19 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
JP2018506278A (ja) * | 2015-01-30 | 2018-03-08 | センター ナショナル ド ラ ルシェルシュ サイエンティフィーク | デルタ133p53ベータおよびデルタ133p53ガンマアイソフォームはがん幹細胞のバイオマーカーである |
JP6990586B2 (ja) | 2015-01-30 | 2022-01-12 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | デルタ133p53ベータおよびデルタ133p53ガンマアイソフォームはがん幹細胞のバイオマーカーである |
CN107921173A (zh) * | 2015-08-03 | 2018-04-17 | 富士胶片株式会社 | 细胞结构体、非人模型动物、非人模型动物的制造方法及被检验物质的评价方法 |
CN107921173B (zh) * | 2015-08-03 | 2021-07-06 | 富士胶片株式会社 | 细胞结构体、非人模型动物、非人模型动物的制造方法及被检验物质的评价方法 |
CN111073889A (zh) * | 2019-12-20 | 2020-04-28 | 中国人民解放军第四军医大学 | 人cspg5基因的用途及相关产品 |
CN111073889B (zh) * | 2019-12-20 | 2023-07-28 | 中国人民解放军第四军医大学 | 人cspg5基因的用途及相关产品 |
CN115840045A (zh) * | 2023-02-23 | 2023-03-24 | 中国农业大学 | 一种猪胚胎期毛囊基板前体细胞的鉴定方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5920725B2 (ja) | 2016-05-18 |
EP2599860A4 (en) | 2013-11-20 |
KR20130080444A (ko) | 2013-07-12 |
CN102906249A (zh) | 2013-01-30 |
US20130198876A1 (en) | 2013-08-01 |
EP2599860A1 (en) | 2013-06-05 |
CA2804119A1 (en) | 2011-12-01 |
JPWO2011148983A1 (ja) | 2013-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5920725B2 (ja) | 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 | |
JP6934501B2 (ja) | 体細胞の再プログラミング | |
JP6023862B2 (ja) | 誘導肝幹細胞及びその製造方法、並びに、該細胞の応用 | |
Tsai et al. | Single transcription factor reprogramming of hair follicle dermal papilla cells to induced pluripotent stem cells | |
Kim et al. | Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors | |
JP6396893B2 (ja) | 合成自己複製RNAによるヒトiPS細胞の作製 | |
EP1734112A1 (en) | Method of proliferating pluripotent stem cell | |
WO2009114949A1 (en) | Methods for deprogramming somatic cells and uses thereof | |
WO2009057831A1 (ja) | 核初期化方法 | |
JP2019058176A (ja) | 新規方法 | |
Zhong et al. | Efficient generation of nonhuman primate induced pluripotent stem cells | |
Setthawong et al. | Generation of porcine induced-pluripotent stem cells from Sertoli cells | |
Chichagova et al. | Generation of human induced pluripotent stem cells using RNA-based Sendai virus system and pluripotency validation of the resulting cell population | |
JP6139054B2 (ja) | 細胞培養基材、およびそれを用いた細胞培養方法並びに多能性幹細胞の分化誘導方法 | |
JP5924741B2 (ja) | 人工癌幹細胞の作製方法及びその分化誘導方法 | |
US8889412B2 (en) | Methods of enhancing pluripotentcy | |
Sfougataki et al. | Reprogramming of bone marrow derived mesenchymal stromal cells to human induced pluripotent stem cells from pediatric patients with hematological diseases using a commercial mRNA kit | |
Facioli et al. | Kidney Organoids Generated from iPS Cells Obtained from the Erythroid Progenitors of Patients with Autosomal Dominant Polycystic Kidney Disease | |
Du et al. | Stem Cells and Nuclear Reprogramming | |
Li et al. | Induced pluripotency: Generation of iPS cells from mouse embryonic fibroblasts | |
Pal | Induced Pluripotent Stem-cell Re-programming in the elderly Prostate | |
Grace et al. | Investigations of Methods for Non-Viral Generation of Bovine Cells to Pluripotency, With a View on Potential Use in Reproductive Technologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180025960.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11786682 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517298 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20127032359 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011786682 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011786682 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11136/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2804119 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13699431 Country of ref document: US |